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”Life is a whim of several billions of cells to be you for a while.”
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Abstract
Finding a suitable material to be used in bone transplantations is a general objective in recon-
structive surgery. Currently, autologous bone transplants are favored by most surgeons due to
their reliability, however availability and donor morbidity are considerable drawbacks of this
treatment. Tissue engineering has developed into a promising alternative, because the variety
of biomaterials and the expertise in stem cell research are both rapidly increasing. The ideal
tissue-engineered bone graft provides biocompatibility, bone-like mechanical stability, osseoin-
tegration and formation of new bone tissue. The goal of this study was to examine scaffolds of
poly D,L-lactic acid (PDLLA), polyetherketoneketone (PEKK), and (hydroxyapatite-modified)
silk from silk worm Bombyx mori in combination with mesenchymal stem cells (MSC) to be
used for the purpose of a tissue-engineered bone graft. The chosen materials offer individual
advantages such as degradability, cost-efficient production, radiolucency and biocompatibility.
MSC are adult multipotent stem cells which are capable of differentiating into osteoblasts upon
stimulation. Therefore, MSC are a frequently applied cell type in bone tissue engineering.
The results of the In vitro tests showed that all scaffolds supported the attachment and osteogenic
differentiation of both human and ovine (sheep origin) MSC. In subsequent in vivo experiments,
scaffolds were implanted either cell-free, seeded with autologous ovine MSC, or seeded with
osteogenically pre-differentiated autologous ovine MSC, into sheep calvarial defects of 10 mm
diameter. After three months, the implants were examined for the volume and quality of newly
formed bone. Surprisingly, the MSC seeding did not result in an enhanced bone formation in
comparison to the cell-free samples. We hypothezise that the absence of the presumed enhancing
effect of MSC was due to a fibrous capsule, which had formed around the scaffolds. Nevertheless,
PEKK and hydroxyapatite-modified silk scaffolds supported new bone formation, either with
or without MSC seeding and are thus potential scaffolds for bone tissue engineering. More
basic research is needed however, to identify relevant factors for improved tissue integration of
transplants, while at the same time avoiding fibrous capsule formation.
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Zusammenfassung
Der Ersatz von Knochengewebe ist ein ha¨ufiges Ziel in der rekonstruktiven Chirurgie. Die
Transplantation autolgen Knochens gilt aktuell aufgrund der hohen Zuverla¨ssigkeit als Gold-
standard, unterliegt jedoch diversen Limitierungen, wie begrenzter Verfu¨gbarkeit und Spender-
morbidita¨t. Fortschritte in Materialwissenschaften und Stammzellforschung machen den Tissue-
engineerten Knochenersatz jedoch zu einer vielversprechenden Alternative. Eigenschaften wie
Biokompatibilita¨t, mechanische Stabilita¨t und die Fo¨rderung neuen, bzw. die Unterstu¨tzung
bereits vorhandenen Knochenwachstums entsprechen den idealen Eigenschaften eines solchen
ku¨nstlichen Knochenersatzes. Ziel dieser Studie war die Untersuchung eines tissue-engineerten
Konstruktes aus einer Kombination von dreidmensionalen (3D) Tra¨germaterialien und mes-
enchymalen Stammzellen. Die Materialien Poly D,L-Lactat (PDLLA), Polyetherketonketon
(PEKK) und (Hydroxylapatit-modifizierte) Seide der Seidenspinnerraupe Bombyx mori wur-
den aufgrund ihrer vorteilhaften Eigenschaften, wie Biodegradierbarkeit, Osteokonduktivita¨t
und Biokompatibilita¨t ausgewa¨hlt. Mesenchymale Stammzellen sind adulte multipotente Stam-
mzellen, die durch entsprechende Stimulation in Osteoblasten differenzieren. Daher sind MSC
ein favorisierter Zelltyp fu¨r das Tissue Engineering des Knochens.
Im ersten Teil der Studie wurde die Kompatibilita¨t der Tra¨germaterialien in Zellkultur u¨berpru¨ft.
Dabei wurden die Adha¨sion und osteogene Differenzierung humaner und oviner (Ursprung Schaf)
MSC von allen Materialien unterstu¨tzt. Im zweiten Teil der Studie wurden die 3D Tra¨germa-
terialien in 10 mm große Defekte der Schafskalotte implantiert, entweder zellfrei, MSC-besiedelt
oder mit osteogen vordifferenzierten MSC-besiedelt. Die MSC entstammten dabei den autologen
ovinen Spendern. Nach drei Monaten wurden die Imlantate auf das Volumen und die Qualita¨t
des neu gebildeten Knochens untersucht. Wider Erwarten, konnte dabei kein Unterschied zwis-
chen den zellfreien und den zellbesiedelten Implantaten festgestellt werden. Das Ausbleiben des
erwarteten Effekts war vermutlich durch die Bildung einer fibrotischen Kapsel um die Implantate
bedingt. Insgesamt wurden aber in den mit PEKK und Hydroxylapatit-modifizierter Seide be-
handelten Defekten (zellfrei oder zellbesiedelt) große Mengen neugebildeten Knochens gefunden.
Damit sind diese Materialien weiterhin fu¨r den potentiellen Einsatz als Knochenersatzmaterial
geeignet. Die spezifische Grundlagenforschung zur fibrosefreien Integration von Biomaterialien
ist jedoch von gro¨ßter Bedeutung fu¨r die zuku¨nftige Forschung im Tissue Engineering.
vi
Contents
1 Introduction 1
1.1 Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Classification of Bones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.2 Structure of Bone Tissue . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.3 Bone Modeling and Remodeling . . . . . . . . . . . . . . . . . . . . . . . 3
1.1.4 Fracture Healing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2 Bone Defects in Cranio-Maxillofacial Surgery . . . . . . . . . . . . . . . . . . . . 5
1.3 Tissue Engineering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.4 Bone Graft Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.4.1 PDLLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.4.2 PEKK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.4.3 Silk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.5 Stem Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.6 Mesenchymal Stem Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.7 Ovine Animal Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.8 Aims of the Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.9 Study Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2 Materials and Methods 17
2.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.1.1 Equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.1.2 Glass Ware . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.1.3 Consumables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.1.4 Chemicals and Solvents . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.1.5 Antibodies for Flow Cytometry . . . . . . . . . . . . . . . . . . . . . . . . 21
2.1.6 Cell Culture Media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.1.6.1 Stem Cell Medium (SCM) . . . . . . . . . . . . . . . . . . . . . 22
2.1.6.2 Osteogenic Induction Medium (OIM) . . . . . . . . . . . . . . . 22
2.1.6.3 Adipogenic Maintenance Medium for human MSC (AMM) . . . 22
2.1.6.4 Adipogenic Induction Medium for human MSC (hAIM) . . . . . 23
2.1.6.5 Adipogenic Induction Medium for ovine MSC (oAIM) . . . . . . 23
vii
2.1.6.6 Chondrogenic Induction Medium (CIM) . . . . . . . . . . . . . . 24
2.1.7 Kits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.1.8 Primers for Realtime PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.1.9 Software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.1.10 Three-dimensional Scaffolds . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.2.1 Culture of Human and Ovine MSC . . . . . . . . . . . . . . . . . . . . . . 27
2.2.1.1 Isolation and Expansion . . . . . . . . . . . . . . . . . . . . . . . 28
2.2.1.2 Surface Epitope Expression . . . . . . . . . . . . . . . . . . . . . 29
2.2.1.3 Osteogenic Differentiation . . . . . . . . . . . . . . . . . . . . . . 29
2.2.1.4 Adipogenic Differentiation . . . . . . . . . . . . . . . . . . . . . 29
2.2.1.5 Chondrogenic Differentiation . . . . . . . . . . . . . . . . . . . . 30
2.2.2 In Vitro Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.2.2.1 Dynamic cell seeding . . . . . . . . . . . . . . . . . . . . . . . . 30
2.2.2.2 Cytotoxicity and Viability . . . . . . . . . . . . . . . . . . . . . 31
2.2.2.3 Alkaline Phosphatase Secretion . . . . . . . . . . . . . . . . . . . 31
2.2.2.4 Alizarin Red Staining . . . . . . . . . . . . . . . . . . . . . . . . 32
2.2.2.5 Quantitative Realtime PCR . . . . . . . . . . . . . . . . . . . . 32
2.2.2.6 Fetuin-A Staining . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.2.3 In Vivo Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.2.3.1 Animal Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.2.3.2 Bone Embedding in Methyl Methacrylate . . . . . . . . . . . . . 36
2.2.3.3 Microradiography . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.2.3.4 Histology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2.2.4 Statistical Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3 Results 40
3.1 Culture of human and ovine MSC . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.1.1 Isolation and Expansion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
3.1.2 Surface Epitope Expression . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.1.3 Osteogenic Differentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.1.4 Adipogenic Differentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.1.5 Chondrogenic Differentiation . . . . . . . . . . . . . . . . . . . . . . . . . 44
viii
3.2 In vitro Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.2.1 Cytotoxicity and Viability . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.2.2 Alkaline Phosphatase Expression . . . . . . . . . . . . . . . . . . . . . . . 49
3.2.3 Alizarin Red Staining . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.2.4 Quantitative Realtime PCR . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.2.5 Alexa488-labeled Fetuin-A Staining . . . . . . . . . . . . . . . . . . . . . 51
3.3 In Vivo Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.3.1 Microradiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
3.3.2 Histology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.3.2.1 Hematoxylin and Eosin Staining . . . . . . . . . . . . . . . . . . 55
3.3.2.2 Movat’s Pentachrome Staining . . . . . . . . . . . . . . . . . . . 63
4 Discussion 67
4.1 Isolation, Expansion and Characterization of Human and Ovine MSC . . . . . . 68
4.2 In vitro analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.2.1 Attachment and Proliferation of MSC on 3D-scaffolds . . . . . . . . . . . 69
4.2.2 Osteogenic Differentiation . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.3 In vivo analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.3.1 Animal Model, Surgery and Sample Preparation . . . . . . . . . . . . . . 72
4.3.2 Immune Response to 3D-Scaffolds . . . . . . . . . . . . . . . . . . . . . . 73
4.3.3 New Bone Formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
5 Conclusion and Perspective 78
Appendix: Histological Stainings 81
Final Disclosures 105
Acknowledgments 107
ix
x
List of Figures
1 Classification of bones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
2 Structure of bones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
3 Stages of bone healing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
4 Poly D,L-lactic acid (PDLLA) resorbable plates and screws . . . . . . . . . . . . 9
5 Polyetherketoneketone (PEKK) cranial implant . . . . . . . . . . . . . . . . . . . 10
6 Bombyx mori silk gland and silk fiber . . . . . . . . . . . . . . . . . . . . . . . . 11
7 Multipotency of mesenchymal stem cells . . . . . . . . . . . . . . . . . . . . . . . 13
8 Schematic overview of the study design . . . . . . . . . . . . . . . . . . . . . . . 16
9 Overview of scaffolds and culture system . . . . . . . . . . . . . . . . . . . . . . . 27
10 Isolation of human and ovine MSC . . . . . . . . . . . . . . . . . . . . . . . . . . 29
11 Animal surgery: Schematic overview of calvarial defects . . . . . . . . . . . . . . 35
12 Methyl methacrylate embedded bone samples . . . . . . . . . . . . . . . . . . . . 37
13 Microradiographic evaluation of newly formed bone . . . . . . . . . . . . . . . . . 39
14 Microscopic pictures and growth curves of human and ovine MSC. . . . . . . . . 41
15 Characterization: Surface Epitope Expression measured with flow cytometry . . 42
16 Characterization: Osteogenic differentiation . . . . . . . . . . . . . . . . . . . . . 43
17 Characterization: Adipogenic differentiation . . . . . . . . . . . . . . . . . . . . . 44
18 Characterization: Chondrogenic differentiation . . . . . . . . . . . . . . . . . . . 45
19 Live/dead staining of cell-seeded scaffolds . . . . . . . . . . . . . . . . . . . . . . 46
20 Cytotoxicity measured via membrane integrity . . . . . . . . . . . . . . . . . . . 47
21 Viability measured via metabolic activity . . . . . . . . . . . . . . . . . . . . . . 48
22 Fluorescence scan of cell-seeded scaffolds . . . . . . . . . . . . . . . . . . . . . . . 49
23 In vitro analysis: Alkaline phosphatase activity . . . . . . . . . . . . . . . . . . . 50
24 In vitro analysis: Alizarin red stainig . . . . . . . . . . . . . . . . . . . . . . . . . 52
25 In vitro analysis: Quantitative realtime PCR . . . . . . . . . . . . . . . . . . . . 53
26 In vitro analysis: Alexa Fluor 488-labeled fetuin-A staining . . . . . . . . . . . . 54
27 In vivo analysis: Microradiography . . . . . . . . . . . . . . . . . . . . . . . . . . 57
28 In vivo analysis: Hematoxylin & Eosin staining . . . . . . . . . . . . . . . . . . . 62
29 In vivo analysis: Movat’s Pentachrome staining . . . . . . . . . . . . . . . . . . . 66
xi
xii
List of Tables
4 Primers for realtime PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
5 Surface epitope expression measured with flow cytometry . . . . . . . . . . . . . 42
6 Microradiographic quantification . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
7 Histomorphometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
8 Annex: Deplastization of histological sections . . . . . . . . . . . . . . . . . . . . 81
9 Annex: Hematoxylin & Eosin staining protocol . . . . . . . . . . . . . . . . . . . 81
10 Annex: Movat’s Pentachrome staining protocol . . . . . . . . . . . . . . . . . . . 82
xiii
xiv
1 Introduction
1 Introduction
1.1 Bone
Bone is a stiff skeletal material made of the fibrous protein collagen, impregnated with the
mineral hydroxyapatite [An & Draughn, 2000]. It has fundamental physiological functions in
that it serves as a mineral reservoir for calcium and phosphate and it provides a niche for blood
formation (hematopoiesis) [Waugh & Grant, 2014]. The hardness, moderate elasticity, and very
limited brittleness of bone make it an ideal tissue for standing and moving, anchoring of muscles,
formation of tendons which make muscles respond, and the protection of soft tissues and organs
[An & Draughn, 2000; Yao, 2007].
1.1.1 Classification of Bones
The human skeleton consists of 206 bones [Hudson, 2006]. Depending on the skeletal sites,
bones may appear as long and tubular segments (long bones), bilaminar plates (flat bones), or
short irregularly prismatic structures (short or sesamoid bones) to which also the bones of the
cranium belong [An & Draughn, 2000]. Figure 1 illustrates examples of each bone type. Long
bones are tubular, they consist of a shaft (diaphysis) and two extremities (epiphysis) [Drake
et al., 2012]. As the name suggests, these bones are longer than they are wide. Examples
include the femur, tibia and fibula. The diaphysis is composed mainly of compact bone, while
the epiphysis consist of a covering of compact bone with spongy bone inside [Bilezikian et al.,
2008]. The diaphysis of long bones contains hematopoietic bone marrow in youth, and yellow
fat repleted, nonhematopoietic marrow in adults [Waugh & Grant, 2014]. One or more nutrient
arteries supply the bone shaft. The sensory nerve usually branches extensively through the
bone, causing severe pain after injury [An & Draughn, 2000]. Short bones are about as long
as they are wide and exhibit a box-shaped structure, examples include the carpals in the wrist.
Flat bones, like that of the cranium, are broad and thin. Irregular bones come in various sizes
and shapes, and they are often clustered in groups, like the sesamoid bones. Short, flat and
irregular bones have a relatively thin outer layer of compact bone with spongy bone inside (see
chapter 1.1.2). All bones are covered by periosteum, except at the inner layer of the calvaria,
where it is replaced by the dura mater Hollinger [2005]. The cranial vault sutures identify the
uniting bones of the skull and are the major side of bone growth in the skull, especially during
the rapid growth of the neurocranium [Bilezikian et al., 2008]. Furthermore, these sutures are
growth centers in which proliferating osteogenic stem cells reside [Hollinger, 2005].
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Figure 1: Bones are classified according to their appearence into long, short, flat and irregular or sesamoid
bones. Adapted without modifications from Blaus [2013].
1.1.2 Structure of Bone Tissue
The major constituent of bone, the inorganic matrix, is a mixture of calcium phosphate and
other minerals. The remaining part is organic osteoid, which consists primarily of collagen. The
combination of mineralized matrix and elastic collagen fibrils leads to the unique hardness and
flexibility of bone tissue [An & Draughn, 2000]. All skeletal segments consist of an outer layer
of compact bone, also called compacta or cortical bone, and an inner zone, the medulla, which
contains the bone marrow [Drake et al., 2012]. Figure 2 illustrates the microscopic structure
of compact bone. The outer layer that covers the surface of cortical bones is the periosteum,
containing mainly blood vessels and osteoblasts, which are activated during appositional growth
and bone repair [Le Meng Bao et al., 2013]. The structural unit of compact bone is the osteon,
or Harversian system. At the center of each osteon is a small channel, called a Harversian canal,
that contains blood vessels and nerve fibers. The osteon itself consists of concentric series of
2
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layers of mineralized extracellular matrix, the lamellae, which surround the central canal [Nordin
et al., 2010] and which give bone its structural strength. Along the boundaries of the lamellae
are small cavities, the lacunae, each containing one mature bone cell, the osteocyte. Numerous
small channels, the canaliculi, radiate from each lacuna, connecting the lacunae of adjacent
lamellae and reaching the Harversian canal [Nordin et al., 2010].
Figure 2: Microscopic structure of compact bone. The basic functional unit of the cortical bone is the
osteon (or haversian system) which consists of extracellular matrix that surrounds the haversian canal.
In the haversian canal, nerves and blood vessels reside. Within the osteon, osteoblasts and the mature
osteocytes are present, which contribute to the generation and maintenance of bone extracellular matrix.
Adapted without modifications from Waugh & Grant [2014].
1.1.3 Bone Modeling and Remodeling
Bone is not a static permanent structure, it is continuously being modeled or remodeled by
specialized cell types [Waugh & Grant, 2014]. Bone modeling is the process by which bone
3
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is formed by osteoblasts without prior bone resorption. This process is crucial during growth
of immature individuals. Bone remodeling, in contrast, occurs throughout life. Osteoclasts
resorb existing bone by releasing lysosomal enzymes and acids, which digest the collagen fibers
and organic matrix, while osteoblasts subsequently form new bone in the same location [Akers
& Denbow, 2013; Bilezikian et al., 2008]. Bone modeling and remodeling achieve strength for
loading and lightness for mobility by strategically depositing bone in locations where it is needed
and by removing bone from where it is not needed. Modeling and remodeling modifies bone
size, shape and mass distribution in adaption to environmental claims [Akers & Denbow, 2013;
Bilezikian et al., 2008].
1.1.4 Fracture Healing
Bone has a substantial capacity for repair and regeneration in response to injury or surgical
treatment [Ai-Aql et al., 2008]. However, bone repair is a complex physiological process. Bone
healing involves the coordinated participation of haematopoietic and immune cells within the
bone marrow together with vascular and skeletal precursor cells, that are recruited from the
surrounding tissues and the circulation [Dimitriou et al., 2005]. The four stages of fracture
healing are depicted in figure 3. In the first stage, immediately following the trauma, a hematoma
is generated which triggers the acute inflammatory response [Akers & Denbow, 2013; Marsell
& Einhorn, 2011]. The inflammatory response is necessary for the healing to progress. The
hematoma coagulates at the injury site, forming a template for callus formation. Here, a brief and
highly regulated secretion of proinflammatory molecules is critical for the regeneration [Marsell
& Einhorn, 2011]. The second stage, the soft callus formation, encompasses chondrogenesis,
endochondral and intramembraneous ossification and angiogenesis. MSC are recruited in order
to differentiate into chondrogenic and osteogenic lineage [Akers & Denbow, 2013; Rentsch et al.,
2014]. However, where these cells exactly come from is not yet fully understood [Marsell &
Einhorn, 2011]. The differentiated chondroblasts produce collagen type II and proteoglycans to
establish mechanical stability. In the third stage, cartilage undergoes hypertrophy and controlled
mineralization. Chondroclasts remove the cartilage as soon as vessels invade so that woven bone
can be formed by osteoblasts [Akers & Denbow, 2013; Rentsch et al., 2014]. In the last stage,
woven bone formation is followed by remodeling, in which the initial hard callus is reshaped to
cortical or trabecular bone to restore the anatomical structure that supports mechanical loads
[Akers & Denbow, 2013; Gerstenfeld et al., 2006]
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Figure 3: Bone healing takes place in four different stages. Hematoma formation (a), soft callus formation
(b), hard callus formation (c) and bone remodelling (d). Adapted without modifications from OpenStax
College [2015].
1.2 Bone Defects in Cranio-Maxillofacial Surgery
With more than 2.2 million bone graft procedures being performed every year worldwide, bone
is currently one of the most frequently transplanted tissues [Im, 2015]. If bone injury exceeds
a critical size, bone regeneration is impaired [Murphy et al., 2013]. These so-called critical size
bone defects are characterized by their deficiency to heal spontaneously during the individiual’s
lifetime [Schmitz & Hollinger, 1986] or at least an extended observation period, so that surgical
intervention is needed [Mardas et al., 2014; Martini et al., 2001]. Critical size bone defects
generally can occur at any bone of the body, they can be caused by major trauma, resection of
malignant tumors or inborn and infectious diseases and highly influence patient’s quality of life
[DeCoster et al., 2004]. The gold standard for treatment is autologous bone grafting. Therefore,
autologous bone blocks are harvested from the fibula, iliac crest, scapula, and radius [Balogh
et al., 2012; Colnot et al., 2005; Tzioupis & Giannoudis, 2007; Zigdon-Giladi et al., 2015], which
are transplanted to the side of the injury. Autologous bone grafting provides osteoconduction,
osteoinduction as well as osteogenesis [Im, 2015]. However, these procedures require extended
hospitalization and a secondary donor site with associated morbidity and complications. In
addition to their surgical complications, these techniques are unpredictable and associated with
significant graft resorption [Iizuka et al., 2004; Lekholm et al., 1999]. As an alternative to
autologous bone grafting, allografts are increasingly studied and applied in clinical cases. Here,
considerable progress has been achieved in the last few decades, especially in terms of mechanical
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stability, shapeability and biocompatiblity. However, the mere biomaterials can only replace the
damaged structure, but cannot mimic its function [Im, 2015]. Therefore, a bone graft generated
by combining living cells with a biomaterial scaffold (tissue engineering) is recently considered
the most pormising future strategy for treating cranio-, maxillofacial bone defects in a sustainable
manner.
1.3 Tissue Engineering
A tissue engineering approach offers several potential benefits, including the lack of donor site
morbidity and the ability to closely mimic the in vivo microenvironment [Zigdon-Giladi et al.,
2015]. Since its emergence in the mid-1980s, tissue engineering has continued to evolve as
a multidisciplinary research field with the aim to develop biological constructs for restoring,
replacing or regenerating defective tissues where the body cannot regenerate the lost tissue
by itself [Alvarez-Barreto, 2007; Chan & Leong, 2008]. Cells, scaffolds and growth-stimulating
signals are generally referred to as the tissue engineering triad, the key components of engineered
tissues [Chan & Leong, 2008]. Cells need to be reproducibly isolated from either the same patient
(autologous cells), and other human donor (allogenic cells) or from an animal source (xenogenic
cells) and need to be reproducibly cultured in vitro without losing their original characteristics
[Planell, 2009]. These cells are then seeded onto biomaterial scaffolds, which are manufactured
in the shape and dimensions desired for the developing tissue. For this purpose, the scaffold is
required to assist the adhesion, proliferation and differentiation of cells to produce the tissue that
needs to be repaired [Planell, 2009]. Biomolecules like growth factors, drugs or genes can be used
to addditionally stimulate the cells to proliferate and differentiate or to recruit progenitor cells
from the surrounding tissue [Fishero et al., 2015]. Another component for tissue engineering
which has been recently introduced, is mechanical stimulation. Works from Li et al. [2015],
Hoffmann et al. [2015], and Kim et al. [2010] impressively demonstrated that stem cells are
sensitive to compression, stretching or shear stress, which can be integrated into culture systems
to further manipulate cell fate. However, the challenge is that all of these single factors have to
be combined in a well-coordinated spatial and time dependent manner [Salgado et al., 2004].
1.4 Bone Graft Materials
Currently, there is no biomaterial which has the same structural, mechanical, chemical and bio-
logical properties of natural bone. Thus, the current gold standard of autologous bone grafting
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is reasonable and also demonstrates that artificially engineered bone tissue does not yet resem-
ble function and form of natural bone, so far. However, in the last decades intensive research
has been undertaken, which generated complex and plentyful information about biomaterials,
scaffolds and cell types for bone tissue engineering. Numerous studies report biomaterials which
achieved favorable results for bone regeneration, but the exact reasons for their beneficial be-
havior are not yet known. Thus, the selection of the appropriate material is a difficult step.
According to Moore et al. [2001], there are at least four general characteristics that an ideal
bone graft material should exhibit:
1. osseointegration, the ability to chemically bond to the surface of bone without an inter-
vening layer of fibrous tissue
2. osseoconduction, the ability to support the growth of bone over its surface
3. osseoinduction, the ability to induce differentiation of stem cells from surrounding tissue
to an osteoblastic phenotype
4. osteogenesis, the formation of new bone by osteoblastic cells present within the graft
material.
Furthermore, ideal bone graft substitutes, from a mechanical point of view, should have a similar
strength to that of the cortical/cancellous bone being replaced. This needs to be matched with
a similar modulus of elasticity to that of bone in an attempt to prevent stress shielding [Moore
et al., 2001]. Additionally, temperature-insensitivity, transmissibility for radiation such as MRI
or x-ray, as well as a rapid and cost-efficient production are desireable characteristics of a bone
substitute.
Up to now several non-degradable or degradable materials from both natural or synthetic
origins have been proposed. Natural materials which have been tested for bone repair in-
clude, but are not limited to, collagen, fibrin, chitosan, hyaluronic acid, hydroxapatite and
poly(hydroxybutyrate), as reviewed in Salgado et al. [2004]. However, synthetic materials offer
the better control of material composition, availability and design, and have been applied more
often in tissue engineering studies. Synthetic materials that are frequently applied are bioglass
[Boccaccini & Blaker, 2005], cements [Zhang et al., 2014], ceramics like β-tricalcium phosphate
[Doernberg et al., 2006; Kolk et al., 2012] and polycaprolactone [Cipitria et al., 2013]. In our
study, the following non-degradable and degradable biomaterials of natural or synthetic origin
were chosen, due to their individual advantageous characteristics.
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1.4.1 PDLLA
Poly D,L-lactic acid (PDLLA) is a degradable synthetic polymer usually applied as membrane
material, degradable plates or screws for fixation of complicated mandibular fractures in children
(figure 4), or as sheets for reconstructing inferior orbital wall defects [Al-Sukhun et al., 2006;
Tatum, 2012]. Degradable biomaterials are especially useful in the growing skull of pediatric
patients [Neumann & Kevenhoerster, 2009]. Moreover, all synthetic bioresorbable polymers can
be very easily fabricated into complex structures by injection molding [Zhang et al., 2009].
Due to a chiral center, polylactic acid can exist in two different isomeric configurations, L-lactic
acid and D-lactic acid. L-lactic acid is mechanically stable but is resorbed slowly, while D-lactic
acid is mechanically less stable but is resorbed fast. By combining these two molecules, many
different polymers can be designed with variable characteristics [Laine et al., 2004]. It has been
reported, that pure poly L-lactic acid, which is crystalline, shows recrystallisation after degra-
dation and thus leads to foreign body reaction. In contrast, the intrinsically amorphous mixture
of 50:50 D,L-lactic acid avoids recrystallisation when degraded [Laine et al., 2004; Suuronen
et al., 2004]. Biodegradation of PDLLA occurs in two phases. During phase one (hydrolysis
phase), water molecules are inserted into the long macromolecule cleaving it into shorter poly-
meric chains. As a result, the device loses structural integrity. During phase two (metabolic
phase), macrophages phagocytize the small polymer fragments, yielding the breakdown products
of lactic acid that are eventually metabolized by the liver into carbon dioxide and water [Imola
et al., 2001].
Although implantation of PDLLA does not require a second surgery, it presents limitations
regarding the ability of providing space for bone formation, mechanical strength, inflammatory
or foreign body reaction during biodegradation, as well as acid release [Hutmacher et al., 1996;
Kinoshita & Maeda, 2013; Tatakis & Trombelli, 1999; Zhang et al., 2009]. Therefore, various
surface modifications of PDLLA, e.g. with hydroxyapatite [Hasegawa et al., 2007; Jensen et al.,
2010; Ren et al., 2008; Zou et al., 2012], calcium phosphate [Heidemann et al., 2001] or chitosan
[Cai et al., 2007] have been suggested. However, commercially available resorbable plates and
screws are still prevalently composed of pure PDLLA [Imola et al., 2001; Tang et al., 2013], as
our scaffolds were in the current study.
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Figure 4: Bioresorbable Poly D,L-lactic acid miniplates and screws as used for osteotomies or in oral
cancer surgery. The material neither interferes with imaging nor with postoperative radiotherapy. The
devices do not need to be removed. Adapted with modifications from [Ketola-Kinnula et al., 2010].
1.4.2 PEKK
Commercialized for industry in the 1980s, polyaryletherketones (PAEKs) are a firmly estab-
lished, FDA approved family of non-degradable thermoplastic polymers, consisting of an aro-
matic backbone molecular chain, interconnected by ketone and ether functional groups [May,
2002]. As the name suggests, PEKK and polyetheretherketone (PEEK) are both members
of the same super family of polyaryletherketones (PAEKs) and exhibit similar characteristics.
While PEEK is an already clinically established bone graft material, PEKK is a relatively
novel commercially available member of the PAEK family. It is gaining increasing importance
as a biomaterial for cranio-facial, orthopedic, and spinal implants (figure 5) [Kurtz & Devine,
2007]. PEAKs are unique in that they are biocompatible, have a similar density and stiffness to
bone, and are radiolucent so as not to interfere with X-Ray equipment [Kurtz & Devine, 2007].
Additionally, they allow for three-dimensional (3D) selected laser sintering, which enables the
production of patient- specific implant geometries, directly printable from computer tomography
(CT)-scans or magnetic resonance imaging (MRI) files [Jalbert et al., 2014]. Nevertheless, the
low surface tension and the chemical and biological inertness also hinder the osseointegration of
PAEKs in the existing bone. Following, a variety of surface or composite modifications have been
proposed for PEKK, too, including hydroxyapatite incorporation [Cook & Rust-Dawicki, 1995;
Kurtz & Devine, 2007; Schwitalla & Mu¨ller, 2013]. These modifications mainly aim at increasing
the bone to implant contact [Mavrogenis, 2009]. In contrast to PEEK, PEKK has a higher sur-
face tension and is thus intrinsically more hydrophilic. Although PEEK is still the most widely
available material of the PAEK family, the benefits of PEKK are increasingly bringing it into
biomedical research, as a potential scaffold for a tissue engineered bone construct.
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Figure 5: OsteoFab
TM
implant for skull reconstruction made of PEKK, a lightweight, chemically
resistant and biocompatible thermoplastic polymer, originally introduced from aerospace engineering now
adopted to biomedical devices. Adapted with modifications from oxford performance materials website
(www.oxfordpm.com; last viewed 13th of May, 2015).
1.4.3 Silk
The silkworm, Bombyx mori, synthesizes vast amounts of silk proteins in its silk glands and
spins them as threads to build a cocoon [Tomita, 2011]. Silkworm silks have been investigated as
biomaterials due to the successful use of silk fibers from B. mori as suture material for centuries
[Altman et al., 2003]. It is considered an advantageous material for tissue engineering because
of the slow degradation [Meinel et al., 2006, 2004] and its various possibilities for modification.
Nowadays, transgenic silk worms are routinely employed to produce silk fibroin loaded with
growth factors like HGF or PDGF [Hino et al., 2006; Tomita, 2011].
Silk proteins are usually produced within specialized glands after biosynthesis in epithelial cells
(figure 6), followed by secretion into the lumen of these glands where the proteins are stored
prior to spinning into fibers [Altman et al., 2003]. The silk fibroin consists of two proteins: a
light chain (26 kDa) and a heavy chain (390 kDa) which are present in an equal ratio and are
connected by a disulfide bond [Zhou et al., 2000]. The amino acid composition of silk fibroin
consists primarily of glycine (43%), alanine (30%) and serine (12%) [Altman et al., 2003; Kaplan
& McGarth, 1998]. The heavy chain consists of twelve domains that form the crystalline part
of the silk fibers, which are interspersed with non-repetitive primary sequence [Altman et al.,
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Figure 6: The silk gland of Bombyx mori larvae consists of three divisions. The posterior silk gland
(PSG) secretes fibroin. The gelatinous sericin components are secreted by different divisions of the middle
silk gland (MSG). The anterior silk gland (ASG) is a mere duct and does not contribute to the secretion
of silk. Silk fibroin was isolated from MSG. Adapted from Tomita [2011].
2003; Zhou et al., 2001]. As shown in figure 6, these core fibroin fibers are encased in a sericin
coat, a family of glue-like proteins that holds two fibroin fibers together to form the composite
fibers of the cocoon case to protect the growing worm [Altman et al., 2003]. Twenty-five to
thirty percent of the silk cocoon mass is sericin, which is in general removed during the de-
gumming process prior to biomedical applications [Altman et al., 2003]. This is known to be
necessary because biological responses to the silk as a suture material had raised concerns about
its biocompatibility regarding inflammation and degradation. Following studies demonstrated
that the sericin glue-like proteins were the major cause of adverse problems and the biological
responses to the fibroin fibers appeared to be improved, if sericin was removed [Kim et al., 2005].
Today, silk fibroin has been applied as a wound dressing or scaffolds for various purposes of
cartilage, tendon and ligament, as well as hepatic, connective or endothelial tissue engineering
[Altman et al., 2003]. It has also been shown that de-gummed silk from B. mori cocoons is a
suitable biomaterial for bone tissue engineering of mouse [Meinel et al., 2005], rat [Meinel et al.,
2006] and rabbit [Kim et al., 2005] critical size bone defects, with low inflammatory reaction
and increased bone healing when seeded with MSC. However, in the current study, we employed
a novel type of silk, produced via a patented method by the company Spintec Engineering,
located in Aachen (Germany). The production of this silk type is based on the fibroin isolation
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directly from the posterior silk gland (figure 6), which is the major fabricant of silk fibroin, not
from cocoons. Therefore the fibroin is isolated before contacting the sericin producing middle silk
gland and is thus naturally sericin-free. As a consequence, this silk type does not need to undergo
de-gumming prior to implantation. The modification of the fibroin with hydroxyapatite (HA)
was possible by mixing the two components into the so-called spinning dope prior to fabrication.
1.5 Stem Cells
Stem cells are unspecialized cells that are defined by their ability to both divide without limit as
needed and, under specific conditions, differentiate into specialized cells [Artmann et al., 2011].
Stem cells are divided into several categories according to their potential to differentiate. The
first morula cells that arise from the division of the zygote are designated totipotent because
they have the capacity to differentiate into any cell that is needed to enable the growth and
development of a whole organism, because they lack the capacity to produce extraembryonic
tissue such as trophoblast cells or placenta cells [Kelly, 2007]. The cells that further develop from
totipotent precursors to the fundamental germ layers of the embryo are designated pluripotent.
Pluripotent cells are like totipotent cells in that they can give rise to all tissue types but they
cannot support the full development of an organism [Kelly, 2007]. Stem cells isolated from the
developing germ layers or its descendend organs can differentiate into multiple organ-specific
cell types. These cells are referred to as multipotent cells. With decreasing hierarchy, stem cells
become oligopotent and are capable of becoming one of a few different cells types, and finally
unipotent, which means a direct progenitor cell of the own specific cell type [Potten, 1997].
1.6 Mesenchymal Stem Cells
Mesenchymal stem cells, also called marrow stromal cells or mesenchymal stromal cells, are
multipotent stem cells [Bianco et al., 2008]. They have the capacity to differentiate into cells of
at least three mesenchymal lineages: bone, fat, and cartilage [Grova et al., 2012; Hoch & Leach,
2014]. In the early 1970’s, Friedenstein and colleagues were the first to report the presence
of fibroblastoid cells that could be flushed out from the adult bone marrow and provided the
first evidence of the existence of what later would be called a mesenchymal stem cell or MSC
[Schipani & Kronenberg, 2009]. More recently, investigators have now demonstrated that multi-
potent MSC can be recovered from a variety of other adult tissues, including adipose tissue,
synovial membrane, umbilical cord, umbilical cord blood and placenta [Asatrian et al., 2015],
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Figure 7: Mesenchymal stem cells are adult multipotent stem cells. They can differentiate into various
cell types of the mesoderm, e.g. osteoblasts, chondrocytes and adipocytes. Their relative ease of harvest
and short self-renewal time make them an attractive source for tissue engineering. Adapted from Risbud
& Sittinger [2002].
and differentiate into numerous tissue lineages including fibroblasts, myoblasts and tenoblasts,
as depicted in figure 7 [Gregory et al., 2005; Risbud & Sittinger, 2002]. In 2006, the Mesenchymal
and Tissue Stem Cell Committee of the International Society for Cellular Therapy published
minimal criteria that classify a cell as a MSC [Dominici et al., 2006; Horwitz et al., 2005]. MSC
are plastic-adherent cells that can differentiate into osteoblasts, chondrocytes, and adipocytes
by adding stimulating medium supplements. They express the surface epitopes CD73, CD90,
and CD105 and do not express CD14, CD11b, CD34, CD45, CD19, and CD79α [Dominici et al.,
2006] The lack of ethical concerns encountered with MSC, compared with embryonic stem cells
[Hoch & Leach, 2014], the multipotency and easy expansion in vitro, as well as their potential in
tissue repair and stem cell therapy, makes MSC of great clinical interest [Gregory et al., 2005].
As a result, numerous preclinical studies have been performed with MSC and clinical trials
are currently ongoing demonstrating efficacy of MSC in human beings for a range of disorders.
For example, bone marrow-derived MSC have demonstrated success in the clinical treatment
of Osteogenesis Imperfecta [Horwitz et al., 1999, 2001] Hurler syndrome [Koc¸ et al., 2002], and
are at the focus of treating other diseases of the musculoskeletal, digestive, integumentary, and
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nervous systems [Hoch & Leach, 2014]. One key characteristic is that MSC may actually inhibit
inflammation and immunological responses in vivo. These immuno-modulatory properties are
probably due to their lack of an HLA type II receptor and the secretion of cytokines [Angoulvant
et al., 2004; Le Blanc, 2003]. In bone fracture repair, MSC play an important physiological
role by differentiating into bone-forming osteoblasts and cartilage-forming chondrocytes. The
cartilage then serves as a template for bone formation through the process of endochondral
ossification [Knight & Hankenson, 2013]. Indeed, MSC are the most commonly applied cell type
in bone tissue engineering studies. Several investigators have already shown the efficacy of local
implantation of MSC in various large animal models, including maxillofacial regeneration [Liu
et al., 2014], spinal fusion [Gan et al., 2008; Zhao et al., 2013], and repair of long bone defects
[Fernandes, Marco Bernardo C et al., 2014; Ve´lez et al., 2012].
1.7 Ovine Animal Model
An appropriate animal model is essential in preclinical studies. Aspects of bone anatomy, strucu-
ture and physiology as well as body weight and biomechanical loads have to be considered for the
best choice. Further aspects that need to be considered are ethical issues, availability handling,
housing and cost efficiency. Sheep are a well-established animal model in cranio-maxillofacial
and orthopaedic research in general [O’Loughlin, 2008; Pearce et al., 2007; Potes, 2008]. They
are used to address the biomechanical, biochemical, and histological processes of bone biology
with experimental design comparable to clinical issues [Potes, 2008]. Additionally sheep are
easy to handle and house, and the cost of purchase and housing is reasonable, permitting large
scale studies [Atayde et al., 2014]. Moreover, they are sufficiently large to allow serial sampling
and multiple experimental procedures, which is advantageous in comparison to small animals
like mouse, rat or rabbit [Martini et al., 2001]. Although sheep cortical bone contains fewer
Haversian canals than does human cortical bone, they seem to have a rate of bone healing and
remodeling that approximates the human rate [Martini et al., 2001].
The critical defect size in each animal model is related to many factors, such as species, breed,
age, or skeletal site, but the most important factor seems to be the relation between bone defect
and size of the selected bone segment [Martini et al., 2001]. The limit of critical size defect
of sheep calvarial defects is not well defined in the literature. However, Martini et al. [2001]
reported that cancellous bone defects having a diameter of 10 mm in sheep are usually critical
size. Although we did not focus on cancellous bone defects in the current study, our defect
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animal model was designed following experiments from Xing et al. [2013], who also reportet a
defect diameter of 10 mm in sheep calvaria to be suitable for the investigation of critical size
bone defects during three months.
1.8 Aims of the Study
Despite decades of research, the ideal combination of biomaterial, scaffold-design and cell type
for a functional tissue engineered bone substitute has not yet been found. Therefore, further
research in this field of study is needed. The goals of the current study were postulated as
follows:
1. The isolation, expansion and characterization of human and ovine MSC
2. The investigation of attachment, proliferation and osteogenic differentiation of human and
ovine MSC on the scaffolds
3. The analysis of quality and volume of newly formed bone after treating critical size defects
from the sheep calvaria with cell-free, MSC-seeded or osteogenically pre-differentiated
MSC-seeded scaffolds.
1.9 Study Design
Figure 8 illustrates the study design. Our study was comprised of an in vitro and an in vivo
experimental part. First, MSC from men and sheep were isolated, expanded and characterized
under optimized culture conditions. In the following steps, human and ovine MSC were seeded
on the scaffolds and the cell attachment was analyzed. Over a period of 21 days, the cytotoxicity,
proliferation and osteogenic differentiation were investigated with in vitro assays. To test the
hypothesis of superior bone regeneration upon implantation of MSC-seeded scaffolds, we cre-
ated critical size defects in the cranial bones of ten one-year-old swifter sheep. For an optimal
comparison, cell-free, as well as MSC-seeded and pre-differentiated MSC-seeded scaffolds of two
material groups were implanted per sheep and additionally one empty defect was created (overall
seven defects per sheep). After a period of three months, the sheep were sacrificed and the sam-
ples were explanted. For analysis of the newly formed bone volume, microradiographic analysis
was performed. Histology was performed to analyze the quality of new bone or inflammation
within the defect.
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Figure 8: Schematic overview of the study design. First, MSC from human and ovine origin were isolated,
expanded and characterized. Secondly, the MSC attachment, proliferation and osteogenic differentiation
were tested on the scaffolds in vitro. Thirdly, cell-free, MSC-seeded and osteogenically pre-differentiated
MSC-seeded scaffolds were implanted in sheep calvarial defects for the duration of three months. The
influence of MSC-seeding on the volume and quality of newly formed bone was evaluated from the
explants.
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2.1 Materials
2.1.1 Equipment
7300 Realtime PCR System Applied Biosystems, Darmstadt, DE
Autoclave 2540 EL Tuttnauer, Breda, NL
Autostainer DAKO Cytomation Dako, Hamburg, DE
Biofuge Pico, Rotor # 3325 Heraeus, Duesseldorf, DE
Biofuge Primo R, Rotor 45
XC # 75007588
Heraeus, Duesseldorf, DE
Camera Canon EOS 1000D Canon, Krefeld, DE
CASY-1 R© Electronic Cell Counter Schaerfe System, Reutlingen, DE
Critical Point Dryer CPD 010 Balzers-Union, Wiesbaden, DE
Diamond Saw EXAKT Otto Hermann Geraetebau, Norderstedt, DE
EM SCD 500 Gold Sputter-Coater Leica, Wetzlar, DE
ESEM XL 30 FEG Electron Microscope FEI Philips, Eindhoven, NL
Embedding Unit Fisher Scientific, Schwerte, DE
FACSCantoTM II Flow Cytometer Becton Dickinson, San Diego, US
Fridge & Freezer Combination Bosch, Munich, DE
Hot Cabinet Heraeus, Duesseldorf, DE
Incubator (20 % O2, 5 % CO2, 37
◦C) Thermo Scientific, Bonn, DE
Laminar Flow Cabinet Heraeus, Duesseldorf, DE
Magnetic Stirrer with Heating IKA, Staufen, DE
Microradiograph Tomoscope Synergy CT-Imaging, Erlangen, DE
Microscope Leica DM IL Leica, Wetzlar, DE
Microscope Leica DMI6000 B Fluorescence Leica, Wetzlar, DE
Microscope Slide Scanner Hamamatsu, Senzaki, JP
Microtome RM2145 Leica, Wetzlar, DE
Microtome Polycut E with size D blade Leica, Wetzlar, DE
Microwave Sharp, Mahwah, US
Mounting Press for Histological Sections Heraeus Kulzer, Wehrheim, DE
Multifuge 3L, Rotor # 75006445 Heraeus, Duesseldorf, DE
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NanoDrop 1000 Fisher Scientific, Schwerte, DE
NanoZoomer 2.0-HT Hamamatsu, Senzaki, JP
Pipette Boy Accu-jet R© Brand, Wertheim, DE
Polisher Saphir 360 ATM, Mammelzen, DE
Slide Stainer Tissue-Tek Sakura, Alphen aan den Rijn, NL
Tecan Infinite M200 R© Microplate Reader Tecan GmbH, Carlsheim, DE
Thermomixers 5436 & Compact Eppendorf, Cologne, DE
Tissue Processor MTM I/II Slee, Mainz, DE
Trephan Drill Oridima, Ortenbach, DE
Typhoon Fluorescence Scanner GE Healthcare, Buckinghamshire, GB
Waterbath GFL, Burgwedel, DE
VacuSafe Comfort INTEGRA Biosciences, Zizers, CH
2.1.2 Glass Ware
Beakers Schott, Mainz, DE
Cover Slips Schott, Mainz, DE
Erlenmeyer & Laboratory Flasks Schott, Mainz, DE
Glass Platelets Roth, Karlsruhe, DE
Pasteur Pipettes Brand, Wertheim, DE
Super Frost Plus Slides Fisher Scientific, Schwerte, DE
2.1.3 Consumables
Bone Marrow Aspiration Needles T-Lok
16 gauge
Angiotech, Vancouver, CA
Capsules Medite, Burgdorf, DE
Cell Strainers Sarstedt, Nuembrecht, DE
Centrifuge Tubes 15 ml & 50 ml Falcon, Franklin Lakes, US
Cryovials 1.8 ml Nunc, Roskilde, DK
Nitrile & Latex Gloves Sempermed, Gevelsberg, DE
Perfusor-Syringes 50 ml Braun, Melsungen, DE
Parafilm ”M” Pechiney, Chicago, US
PCR reaction plates Applied Biosystems, Darmstadt, DE
Pipettes 5 ml, 10 ml & 25 ml Falcon, Franklin Lakes, US
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Pipette Tips 10µl Nerbeplus, Winsen/Luhe, DE
Pipette Tips 200 µl Sarstedt, Nuembrecht, DE
Pipette Tips 1000µl Heinz Herenz, Hamburg, DE
Pleated Filters Merck, Darmstadt, DE
Polyethylen Films Heraeus Kulzer, Wehrheim, DE
Reaction Tubes 1.5 ml & 2 ml Eppendorf, Cologne, DE
Resorbable Sutures Ethicon, Hamburg, DE
Round Bottom Tubes for Flow Cytometry BD Biosciences, Heidelberg, DE
Tissue Culture & Multiwell Plates BD Biosciences, Heidelberg, DE
Sterile Filters 0.22µm Merck, Darmstadt, DE
Sterile Filters, Bell-shaped 500 ml Sartorius, Goettingen, DE
2.1.4 Chemicals and Solvents
Acetic Acid Merck, Darmstadt, DE
Acetone Sigma-Aldrich, Steinheim, DE
Agarose Merck, Darmstadt, DE
Alcian Blue Powder Sigma-Aldrich, Steinheim, DE
Alexa Fluor 488 Life Technologies, Darmstadt, DE
Alizarin Red Powder Sigma-Aldrich, Steinheim, DE
Ammonium Hydroxide Sigma-Aldrich, Steinheim, DE
Aqua ad Injectabilia Braun, Melsungen, DE
Atropin Braun, Melsungen, DE
β-mercaptoethanol Invitrogen, Darmstadt, DE
Caprofen Pfizer, Karlsruhe, DE
Cefuroxim Roche, Basel, CH
Dapi I Abbot, Wiesbaden, DE
Dimethylsulfoxide (DMSO) Merck, Darmstadt, DE
1.107 % Di-Sodium-AEDTA AlleMan Pharma, Rimbach, DE
DNAse I from Bovine Pancreas Sigma-Aldrich, Steinheim, DE
Ethanol Sigma-Aldrich, Steinheim, DE
Eosin Sigma-Aldrich, Steinheim, DE
Ficoll-Hypaque LSM 1077 PAA, Coelbe, DE
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FCS Lonza, Basel, CH
Fetuin-A, bovine Sigma-Aldrich, Steinheim, DE
Fluoresceindiacetate (FDA) Sigma-Aldrich, Steinheim, DE
Fluorescent mounting medium Dako, Glostrup, DN
Formaldehyde Fischar, Saarbruecken, DE
Glutaraldehyd Merck, Darmstadt, DE
Hematoxylin Sigma-Aldrich, Steinheim, DE
Human Recombinant Epidermal Growth Factor Biochrom, Berlin, DE
Human Recombinant Bone Morphogenic
Protein-7 (BMP7)
Sigma-Aldrich, Steinheim, DE
Human Recombinant Transforming growth
factor β-1 (TGF-β1)
Sigma-Aldrich, Steinheim, DE
Human Recombinant Transforming growth
factor β-3 (TGF-β3)
R&D Systems, Wiesbaden, DE
Isofluran Lilly, Giessen, DE
2-Methoxyethylacetat (2-MEA) VWR, Darmstadt, DE
Meyer’s Hematoxylin Merck, Darmstadt, DE
Movat’s Staining Solution Morphisto, Frankfurt Main, DE
Oil Red O Powder Sigma-Aldrich, Steinheim, DE
Paraffin Leica, Wetzlar, DE
Paraformaldehyde Merck, Darmstadt, DE
Pentaorbital Mallinckrodt, Burgweser, DE
Phosphate Buffered Saline (PBS) Gibco/Invitrogen, Darmstadt, DE
Phosphotungstic Acid Powder Merck, Darmstadt, DE
Power SYBR Green Applied Biosystems, Darmstadt, DE
Propidium Iodide (PI) Sigma-Aldrich, Steinheim, DE
Propofol Braun, Melsungen, DE
Rubber Cement Marabu, Tamm, DE
Ringer’s Solution Delta-Pharma, Pfullingen, DE
Saffron du Gatinais Morphisto, Frankfurt Main, DE
Sandpaper 800-grit HERMES, Hamburg, DE
Soerensens’s Phosphate Buffer Merck, Darmstadt, DE
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Sodium Hydroxide (NaOH) Sigma-Aldrich, Steinheim, DE
Trypsin-EDTA % Lonza, Cologne, DE
Thrombin From Human Plasma Sigma-Aldrich, Steinheim, DE
Toluidine Blue Powder Sigma-Aldrich, Steinheim, DE
Weigert’s ferric hematoxylin A and B Morphisto, Frankfurt Main, DE
Vitro-Clud R© Langenbrinck, Emmendingen, DE
Xylazin Roche, Basel, CH
Xylene VWR, Darmstadt, DE
2.1.5 Antibodies for Flow Cytometry
Antibodies reactive against human species
CD29-PE BD Pharmingen, Heidelberg, US
CD45-APC BD Pharmingen, Heidelberg, DE
CD73-APC BD Pharmingen, Heidelberg, DE
CD90-FITC BD Pharmingen, Heidelberg, US
CD105-FITC BD Pharmingen, Heidelberg, US
CD166-PE BD Pharmingen, Heidelberg, US
Antibodies reactive against ovine species
CD44-FITC AbD Serotec, Puchheim, DE
CD45-FITC AbD Serotec, Puchheim, DE
Isotype controls
FITC IgG 2A κ BD Pharmingen, San Diego, US
PE IgG 2A κ BD Pharmingen, San Diego, US
APC IgG 2A κ BD Pharmingen, San Diego, US
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2.1.6 Cell Culture Media
2.1.6.1 Stem Cell Medium (SCM)
Stem cell medium for mesenchymal stem cells (Mesenpan) was purchased from PAN Biotech
(Aidenbach, DE). The following components were added:
- 2 % FCS PAN Biotech, Aidenbach, DE
- 100 U/ml Penicillin PAA, Coelbe, DE
- 100µg/ml Streptomycin PAA, Coelbe, DE
- 2 mM L-Glutamine PAA Coelbe, DE
2.1.6.2 Osteogenic Induction Medium (OIM)
Dulbecco’s Modified Eagle Medium (DMEM)
1 g/l glucose
PAA, Coelbe, DE
+ 10 %FCS PAN Biotech, Aidenbach, DE
+ 100 nM Dexamethasone Sigma-Aldrich, Steinheim, DE
+ 10 mM β-glycerophosphate Sigma-Aldrich, Steinheim, DE
+ 0.05 mM L-Ascorbic Acid Sigma-Aldrich, Steinheim, DE
+ 100 U/ml Penicillin PAA, Coelbe, DE
+ 100µg/ml Streptomycin PAA, Coelbe, DE
+ 2 mM L-Glutamine PAA, Coelbe, DE
2.1.6.3 Adipogenic Maintenance Medium for human MSC (AMM)
DMEM 4.5 g/l glucose PAA, Coelbe, DE
+ 10 %FCS PAN Biotech, Aidenbach, DE
+ 0.01 mg/ml Human Insulin Sigma-Aldrich, Steinheim, DE
+ 100 U/ml Penicillin PAA, Coelbe, DE
+ 100µg/ml Streptomycin PAA, Coelbe, DE
+ 2 mM L-Glutamine PAA, Coelbe, DE
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2.1.6.4 Adipogenic Induction Medium for human MSC (hAIM)
Adipogenic Maintenance Medium see chapter 2.1.6.3
+ 0.2µM Indomethacin Biomol, Hamburg, DE
+ 1µM Dexamethasone Sigma-Aldrich, Steinheim, DE
+ 0.5 mM IBMX Sigma-Aldrich, Steinheim, DE
2.1.6.5 Adipogenic Induction Medium for ovine MSC (oAIM)
DMEM 4.5 g/l glucose PAA, Coelbe, DE
+ 10 %FCS PAN Biotech, Aidenbach, DE
+ 0.01 mg/ml Human Insulin Sigma-Aldrich, Steinheim, DE
+ 200µM Indomethacin Biomol, Hamburg, DE
+ 0.5 mM IBMX Sigma-Aldrich, Steinheim, DE
+ 100 U/ml Penicillin PAA, Coelbe, DE
+ 100µg/ml Streptomycin PAA, Coelbe, DE
+ 2 mM L-Glutamine PAA, Coelbe, DE
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2.1.6.6 Chondrogenic Induction Medium (CIM)
DMEM 4.5 g/l glucose PAA, Coelbe, DE
+ 100 nM Dexamethasone Sigma-Aldrich, Steinheim, DE
+ 0.17 mM L-ascorbic acid-2-phosphate Sigma-Aldrich, Steinheim, DE
+ 100µg/ml Sodium Pyruvate Sigma-Aldrich, Steinheim, DE
+ 40 µg/ml Proline Sigma-Aldrich, Steinheim, DE
+ 5 ml ITS-Plus Sigma-Aldrich, Steinheim, DE
+ 100 U/ml Penicillin PAA, Coelbe, DE
+ 100µg/ml Streptomycin PAA, Coelbe, DE
+ 2 mM L-Glutamine PAA, Coelbe, DE
For human MSC:
+ 10 ng/ml TGF-β3 (fresh) R&D Systems, Wiesbaden, DE
For ovine MSC, instead of TGF-β3:
+ 100 ng/ml BMP7 Sigma-Aldrich, Steinheim, DE
+ 10 ng/ml TGF-β1 (both fresh) Sigma-Aldrich, Steinheim, DE
2.1.7 Kits
CellTiter Blue R© Cell Viability Assay Promega, Mannheim, DE
CytoTox-ONETM Homogenous Membrane
Integrity Assay
Promega, Mannheim, DE
RNeasy R© Mini Kit Qiagen, Hilden, DE
High Capacity cDNA Reverse Transkription
Kit
Life Technologies, Darmstadt, DE
Quantitative alkaline phosphatase ES
characterization kit
Merck Millipore, Istanbul, TR
Technovit R© 91000 Combi Package Heraeus Kulzer, Wehrheim, DE
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2.1.8 Primers for Realtime PCR
Human primers were chosen and employed following established protocols from our working
group as cited in Kramann et al. 2013 Kramann et al. [2013]. Ovine primers were designed with
Basic Local Alignment Search Tool (BLAST) and the primer3web version 4.0.0. All Primers
were purchased from Eurofins MWG (Ebersberg, DE) and tested beforehand for suitable melting
curves, melting temperatures and CT-values, with human and ovine MSC cultured in SCM and
OIM.
Table 4: Primers for Realtime PCR
Primer Sequence Size in BP
Human Primers
GAPDH for 5’-GAA GGT GAA GGT CGG AGT CA-3’ 108
rev 5’-AAT GAA GGG GTC ATT GAT GG-3’
ALP for 5’-CCG TGG CAA CTC TAT CTT TGG-3’ 88
rev 5’-CAG GCC CAT TGC CAT ACA G-3’
BMP2 for 5’-ACA AAC AGC GGA AAC GCC T-3’ 73
rev 5’CCA CCC CAC GTC ACT GAA G-3’
Runx2 for 5’-GCA AGG TTC AAC GAT CTG AGA TT-3’ 73
rev 5’-AAG ACG GTT ATG GTC AAG GTG AA-3’
Ovine Primers
β-2 microglobuline for 5’-GCC ATC CAG CGT ATT CCA G-3’ 132
rev 5’-CCC GTT CTT CAG CAA ATC G-3’
ALP for 5’-CGT GAC TGA CCC TTC ACT CT-3’ 245
rev 5’-AGG TAA AGA CGT GGG AGT GG-3’
BMP2 for 5’-TGG GGT GGA ATG ACT GGA TC-3’ 301
rev 5’-CAG CAT GCC TTG GGA ATC TT-3’
Runx2 for 5’-GGA CGA GGC AAG AGT TTC AC-3’ 427
rev 5’-GGT GGC AGT GTC ATC ATC TG-3’
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2.1.9 Software
i-Control Microplate Reader Software Tecan GmbH, Carlsheim, DE
IMALYTICS Preclinical 2.0 Institute of Experimental Molecular Imaging,
RWTH Aachen, Aachen, DE
FACSDiva Becton Dickinson, Heidelberg, DE
FlowJo version 10 FLOWJO LLC, Ashland, US
Graphpad Prism 6.0 GraphPad Software Inc., La Jolla, US
LATEX Open Source
Microsoft Office 2010 Microsoft Corporation, Redmond, US
NDP.view 2 Hamamatsu Photonics, Senzaki, JP
Primer3web version 4.0.0 Whitehead Institute for Biomedical Research,
Camebridge, USA
2.1.10 Three-dimensional Scaffolds
All biomaterials were obtained as three-dimensional (3D) scaffolds with a diameter of 0.9 cm
and a height of 0.7 cm. Bio-degradable poly-D,L-lactic acid (PDLLA) scaffolds were produced
by KLS Martin GmbH (Munich, Germany) through injection molding. As depicted in figure 9 a,
PDLLA scaffolds consisted of the racemic bulk material without any interconnecting channels,
scaffols were gamma sterilized. Non-degradable polyetherketoneketone (PEKK) scaffolds with
rectangularly interconnected channels of 600µm diameter figure 9 a were provided by Oxford
Performance Materials (South Windsor, USA). They were made by selective laser sintering, an
additive manufacturing procedure in which PEKK polymer powder is melted one layer at a time.
For sterilization, the PEKK scaffolds were autoclaved for 30 min at 121 ◦C and 2 bar pressure.
Silk implants made from bombyx mori (silk worm) silk were provided by Spintec Engineering
(Aachen, Germany). Native sericin-free silk was isolated from the silk glands and biocasted
into a flat membrane. On top of the flat membrane a network of biospinned silk fibers with a
diameter of approximately 70µm in varying orientation was assembled, as shown in figure 9 a.
The assembled silk fibers consisted either of unmodified silk or were loaded with 40 mg/g of
hydroxyapatite (silk + HA). For disinfection, the silk scaffolds were transferred to sterile, non-
surface-treated 24-well plates and immersed in 70 % ethanol for 1 h. The ethanol was aspirated
and the scaffolds were dried within the laminar flow cabinet overnight. The silks were then
stored in a sterile well-plate. The swimming biomaterial scaffolds PDLLA and PEKK were
submerged in culture medium with a 10 µl pipette tip, which was previously glued to the lid
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Figure 9: Scaffold culture. (A) Images of photographed 3D scaffolds. Scaffolds were 10 mm in diameter,
non-porous PDLLA and porous PEKK were 7 mm high, and silk was approximately 2-3 mm high,
depending on the randomly oriented silk fibers on top of the membrane. B) The schematic overview
shows the scaffold culture in a 24-well plate. Swimming PDLLA and PEKK were kept submerged in cell
culture medium with a pipet tip, glued to the lid of the 24-well plate. This was not necessary for Silk (+
HA). Cytotoxic effects of the glue and/or the pipet tip have been excluded in pre-experiments (data not
shown).
of the 24-well plate with rubber cement. The glue was evaporated for about 16 h prior to cell
seeding. This setup secured the complete coverage of the scaffolds with medium and prevented
them from exposure to air (figure 9b). Cytotoxic effects of the glue and pipette tip on MSC
have been excluded beforehand.
2.2 Methods
2.2.1 Culture of Human and Ovine MSC
Human tissue was received after informed consent and the procedure was approved by the RWTH
Aachen University Committee on Ethics in Medicine. All animal experiments were carried out
according to rules of the RWTH Aachen Institute for Laboratory Animal Research (ILAR)
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and the Federation of European Laboratory Animal Science Association (FELASA) and were
approved by an Animal Experimentation Ethics committee appointed by the state of North-
Rhine Westfalia. In general, cell cultures were handled sterilely under a laminar flow cabinet
and incubated in a 20 % O2 and 5 % CO2 humidified atmosphere at 37
◦C.
2.2.1.1 Isolation and Expansion
Human MSC were isolated as described by [Haynesworth et al., 1992] and Pittenger [Pittenger,
1999]. Bone marrow spongiosa (figure 10) of patients with total hip joint endoprosthesis (TEP)
was rinsed with stem cell medium (SCM) several times. The flushed medium was centrifuged
for 10 min at 500 g. Subsequently, the cell pellet was resuspended in 10 ml of SCM and seeded
in a 75 cm2 culture flask. Ovine MSC were isolated out of 40 mL bone marrow aspirate from
Rhoen sheep iliac crest (figur 10), which were supplemented with 2 mL 1.107 % Di-Sodium-
AEDTA to prevent the samples from coagulation. Mononuclear cells were harvested by Ficoll R©
density gradient centrifugation (density 1.077 g/mL) and subsequently seeded in 75 cm2 tissue
culture flasks in 10 ml of SCM. After 24 h, non-adherent cells from both species were removed by
medium change. For optimal expansion, the medium was changed every 3 to 4 days. At 80 - 90 %
confluence, stem cells were trypsinized with 4 ml of trypsin-EDTA, which was incubated for 4 -
5 min. Subsequently, 6 ml SCM were added to decelerate the trypsin digestion and the cells were
harvested in a 50 ml centrifuge tube. After 7 min of centrifugation, the supernatant was discarded
and the cell pellet was reseeded in SCM at a density of 5.000 cells/cm2 for human MSC or 10.000
cells/cm2 for ovine MSC, respectively. MSC adherence and morphology were investigated at 10-
fold magnification with a light microscope. Pictures were taken 9 days after isolation. For
storage, 500.000 MSC were transferred into a cryovial in 1 ml of SCM containing 10 % DMSO.
After 1 h incubation at −20 ◦C, the cells were transferred to −80 ◦C for one day and afterwards
stored in the vapour phase of a liquid nitrogen container. For defrosting, cryopreserved cells
were inoculated in 5 ml SCM, centrifuged for 7 min at 500 g resuspended in 10 ml of fresh SCM
and seeded in a tissue culture flask. Human and ovine MSC were characterized according to
the standard protocols as required by the International Society for Cellular Therapy [Horwitz,
Dominici]. A comparison of differentiation protocols for ovine MSC was published in Adamzyk
et al. Adamzyk et al. [2013].
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Figure 10: MSC were isolated from ovine bone marrow aspirates (left) and human spongiosa which
was obtained after hip TEP from the femoral head (right). Bone marrow aspirates were processed via a
density centrifugation. Spongiosa was flushed with stem cell medium.
2.2.1.2 Surface Epitope Expression
For analysis of the surface epitopes, MSC were trypsinized, counted and washed in PBS. After-
wards, 200.000 cells/100µl PBS were incubated with 3µl of a FITC-/PE-/or APC-conjugated
primary antibody on ice for 45 min in the dark. After centrifugation (3 min at 500 g), the cells
were resuspended in 200µl PBS and transferred to FACS tubes for measurement. Isotype incu-
bated cells served as a control and at least 10.000 events were measured from each sample.
2.2.1.3 Osteogenic Differentiation
In a 24-well plate, 31.000 human MSC/cm2 and 50.000 ovine MSC/cm2 were seeded in SCM.
After 24 h, the medium was changed and the cells were further cultured in osteogenic induction
medium (OIM, see 2.1.6.2) or SCM as an undifferentiated control. Media were changed three
times per week. The accumulation of calcium nodules following osteogenic differentiation was
photographed and quantified with Alizarin red staining as described in chapter 2.2.2.4.
2.2.1.4 Adipogenic Differentiation
In a 24-well plate, human MSC were seeded in a density of 80.000 cells/cm2, ovine MSC in a den-
sity of 30.000 cells cells/mm2. After 24 h, adipogenic induction media hAIM (chapter 2.1.6.4)
and oAIM (chapter 2.1.6.5) were added to the cells. Control cells were further cultured in
SCM. Treatment of human MSC with hAIM and adipogenic maintenance medium (AMM, chap-
ter 2.1.6.3) alternated with each medium change. Ovine MSC were consecutively treated with
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oAIM. Media were changed three times per week. The formation of lipid droplets was visualized
after Oil Red O staining. Here, the cells were fixed in 50 % ice cold ethanol for 30 min. The
cells were then incubated for 10 min in Oil Red O staining solution (35 ml of a 0.2 % (w/v) Oil
Red O powder in 100 % methanol + 10 ml 1 M NaOH) on a rocker. Afterwards, the cells were
shortly washed in 50 % EtOH again and photographed in Aqua dest..
2.2.1.5 Chondrogenic Differentiation
Human MSC at a concentration of 250.000 cells in 0.5 ml and ovine MSC in a concentration of
500.000 cells in 0.5 ml were transferred to a 15 ml centrifuge tube. After 12 min of centrifugation
at 500 g, a cell pellet was produced, which was subsequently cultured either in SCM or in
chondrogenic induction medium (CIM, chapter 2.1.6.6). The media were changed three times
per week. The growth factors TGF-β3 for human MSC, and TGF-β1 and BMP7 for ovine MSC,
were always added freshly to the medium. After 21 days of culture, the pellets were fixed in
4 % formalin, embedded in agarose and dehydrated in an ascending ethanol series in a tissue
processor. Afterwards, the pellets were embedded in paraffin and sectioned with a rotating
microtome into slices of 7µm thickness and stained with Toluidine Blue (1 g Toluidine Blue
powder in 100 ml acetate buffer, pH 4.66) for 5 min to visualize proteoglycans and extracellular
matrix.
2.2.2 In Vitro Analyses
2.2.2.1 Dynamic cell seeding
MSC were trypsinized and diluted to a concentration of 106 cells in 3 ml of stem cell medium for
dynamic cell seeding on the scaffolds. The biomaterials were each placed in a small glass vial
(5 ml volume, screw-cap) together with the 3 ml cell suspension. The glass vials, including cell
suspension and scaffold, were rotated on a roll shaker for 5 min at RT. Afterwards, the vials
were left in the incubator for 20 min without shaking. Finally, the glass vials were placed on
the roll shaker again for 5 min. Afterwards, cell seeded biomaterials were placed in 24-well cell
culture plates and incubated in 1.5 ml fresh SCM. The control condition underwent the same
procedure, only without a scaffold in the glass vial. From the control vial 5 × 104 viable cells
were seeded on TCPS and incubated in 1 ml of fresh SCM. The scaffolds and controls were kept
in culture as described in chapter 2.1.10.
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2.2.2.2 Cytotoxicity and Viability
To instantly measure cytotoxic effects, a live/dead staining of stem cells on biomaterials was
performed 24 h after seeding, according to the protocols 10993-5 of the International Standard-
ization Organization (ISO). The cell-seeded scaffolds were stained with a droplet of a mixture
of 20µl fluoresceindiacetate (FDA) and 20µl propidium iodide (PI) added to 1.2 ml of Ringer’s
solution. After an incubation time of 20 s, the samples were visualized under a fluorescence
microscope. FDA is taken up by cells which convert the non-fluorescent FDA into the green
fluorescent metabolite fluorescein. In contrast, the red fluorescent PI can only pass through
disordered areas of dead cell membranes and intercalate with nucleic acids (DNA/RNA). There-
fore, viable cells were positive for green fluorescent FDA and necrotic cells were positive for
red fluorescent PI. Exemplary overview images of the green FDA channel were taken with the
Typhoon fluorescence scanner after 21 days of culture (figure 22).
For constantly monitoring the cytotoxicity over 21 days, the CytoTox ONETM homogenous
membrane integrity assay was conducted. This assay detects the release of lactate dehydrogenase
(LDH) from cells with a damaged membrane by a shift in the fluorescence maximum of the
reagent. The amount of fluorescence units produced is proportional to the number of lysed cells
Niles et al. [2009]. On day 1, 7, 14 and 21, 100µl of supernatant of the cell-seeded scaffolds
were transferred into a black 96-well plate and incubated for 10 min at RT with the same
volume of cytotoxicity reagent. Afterwards, 50µl of stop solution were added and the plate
was kept in the dark until measurement. The metabolic activity of the cells was measured with
the CellTiter-Blue R© cell viability assay. Therefore, 1.5 ml culture medium containing 20 % of
viability reagent were added to the cell-seeded scaffolds and incubated for 1 h. The supernatant
was then transferred into a black 96-well plate. Cytotoxicity and viability were both measured
from individual samples at each time point in order to rule out potential influences of the
CellTiter-Blue R© accumulated reagent on the proliferation of the cells. Fluorescence values were
measured with a plate reader at an excitation and emission wavelength of 560 nm and 590 nm,
respectively.
2.2.2.3 Alkaline Phosphatase Secretion
Alkaline phosphatases (ALPs) are membrane-bound ectoenzymes that hydrolyze monophosphate
esters at a high pH (8 - 10). Human ALP is classified into 4 types - tissue-nonspecific, intestinal,
placenta, and germ cell - of which the tissue-nonspecific type is ubiquitously expressed in many
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tissues, including liver, bone, and kidney Orimo [2010]. ALPs play a key role not only in
calcification but also in bone resorption, by removing the layer of pyrophosphate which covers
the mineral surface of bone and which has been shown to retard the deposition rate of calcium
and phosphate onto this surface Warnes [1972]. In cell culture, ALP is secreted by MSC into the
surrounding culture medium. The secretion increases with beginning osteogenic differentiation
and peaks approximately at day 14 until it decreases again at day 21 after osteogenic induction.
Therefore, the supernatant from scaffold cultures was collected in reaction tubes on days 7,
14 and 21 of differentiation from the same sample, for the detection of ALP activity with
the quantitative alkaline phosphatase ES characterization kit. The quantitative evidence is
based on the ability of ALP to hydrolyze the substrate p-nitrophenylphosphate (p-NPP) into
phosphate and the yellow by-product p-nitrophenol. The amount of yellow p-nitrophenol can
be measured with a spectrophotometer and is proportional to the amount of active ALP. Fifty
µl of supernatant were mixed with 50µl 2xpNPP-substrate solution and incubated in the dark
for 20 min. By adding 25µl of 3 M NaOH the reaction was stopped and the extinction of the
mixture was measured in a plate reader at 405 nm.
2.2.2.4 Alizarin Red Staining
After 21 days of osteogenic differentiation, cells were stained with Alizarin red to detect calcium
deposits. Before staining, the samples were fixed in 4 % formalin for 30 min, washed three times
with Aqua dest. and then stained with Alizarin red solution (40 mM, pH 4.1) for 20 min. After 3
washing steps with Aqua dest., the samples were photographed macro- and microscopically. For
quantification, 800µl of 10 % acidic acid were added to the scaffolds and after 30 min incubation
the cells were scraped off the surface of the scaffolds with a pipet tip and transferred into a 1.5 ml
centrifuge tube. The supernatants were heated to 85 ◦C for 10 min and cooled down on ice for
5 min. Afterwards, the supernatants were centrifuged for 15 min at 1600 g. Of each sample,
200µl were mixed with 100µl of 10 % ammonium hydroxide. The absorption of 150µl of this
final mixture was measured in duplicates on a plate reader at 405 nm.
2.2.2.5 Quantitative Realtime PCR
Runt-related transcription factor-2 (Runx2), bone morphogenic protein 2 (BMP2) and alkaline
phosphatase (ALP) expression levels between MSC cultured in SCM and in OIM were measured.
One microgram of isolated messenger RNA (mRNA) was reverse transcribed into complementary
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DNA (cDNA) using the high capacity cDNA Reverse Transcriptase Kit. Quantitative PCR
reactions were carried out with Power SYBR Green PCR Master Mix, using 1.2 µl of cDNA
template per reaction. Amplification was monitored with the ABI Prism 7300. The expression
of genes of interest was normalized against the housekeeping genes (table 4) in all samples, and
gene expression was calculated with the 2−∆∆CT method.
2.2.2.6 Fetuin-A Staining
Fetuin-A is a liver-derived blood protein that acts as a potent inhibitor of ectopic mineraliza-
tion and which binds small clusters of calcium and phosphate in vivo Brylka & Jahnen-Dechent
[2013]Jahnen-Dechent et al. [2011]. To visualize precipitated calcium phosphate after 21 days,
in addition to Alizarin red staining, we used Alexa Fluor 488-labeled fetuin-A and fluorescence
microscopy. Bovine fetuin-A was purified via size exclusion chromatography before being con-
jugated to Alexa Fluor 488, according to the manufacturer’s instructions. The samples were
fixed 30 min in 0.5 % paraformaldehyde at RT. After three washing steps in PBS, the samples
were incubated in PBS containing 0.5 mg/ml Alexa Fluor 488-labeled fetuin-A, for 1 hour at RT.
After three washing steps with PBS, the samples were counterstained with 1µg/ml Dapi in PBS,
covered with fluorescence mounting medium and photographed using fluorescence microscopy.
2.2.3 In Vivo Analyses
2.2.3.1 Animal Surgery
All surgical procedures were performed under general anesthesia and aseptic conditions. In
total, 10 one-year old Rhoen Sheep with an average weight of 70 kg were operated. Anesthesia
was induced by application of 2 % Xylazin, 10 mg Atropin, and 2 % Propofol. After intubation,
the anesthesia was maintained by inhalation of 1.5 % Isofluran and 30 % oxygen. Analgesia
consisted of 8 % Caprofen for 3 days postoperatively. Antibiosis was provided by application of
1.5 g Cefuroxim.
The skull of the sheep was shaved and washed for desinfection. The cranium was exposed by
a sagittal scalp incision. The skin was reflected and the periosteum was irreversibly removed
until the parietal bones were exposed. Seven circular, 1 cm diameter, full-thickness defects were
induced with a trephan drill. Special care was taken not to damage the underlying dura and
sagittal sinus. As depicted in figure 11, two material types comprising cell-free, MSC-seeded and
predifferentiated MSC-seeded scaffolds and an additional empty defect could be placed in one
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animal. Cell-free scaffolds were incubated in SCM for 21 days just like the cell-seeded scaffolds
for better comparability. After insertion of the implants with the help of forceps, the skin flap
was repositioned and the wound closed with resorbable sutures. After 12 weeks, the animals
were sacrificed under anesthesia by an overdose of pentobarbital and the defect regions were
explanted using a rotating bone saw.
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Figure 11: Seven calvarial defects of 10 mm diameter were induced in the parietal/occipital bones with
a trephan drill in ten sheep. (A) Two biomaterials could be placed in one animal at the same time.
The biomaterials were inserted either cell-free, MSC-seeded (+MSC) or seeded with osteogenically pre-
differentiated MSC (+MSC diff.). As a control, an empty defect was created whithout the insertion of
any biomaterial. Incubation time was 12 weeks. (B) Exemplary pictures of the inserted biomaterials
PDLLA, PEKK and silk (+ HA). Because of their smaller height, four individual silk sheets (4×silk)
were placed per defect.
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2.2.3.2 Bone Embedding in Methyl Methacrylate
Immediately after explantation, the samples were fixed in freshly prepared 4 % paraformaldehyde
for 2 days at 4 ◦C. The samples were dehydrated in a tissue processor with an ascending ethanol
series of 2×70 %, 2×96 %, and 3×100 % followed by 3×Xylene, each for 1 h. Afterwards, the
samples were infiltrated and embedded in methyl methacrylate, using the Technovit 9100 New R©
combi package. The solutions were employed following the manufacturer’s instructions:
1. Xylene/Technovit basic solution (stabilized), 1 day at RT
2. Technovit basic solution (de-stabilized)/Hardener 1, 1 day at 4 ◦C
3. Technovit basic solution (de-stabilized)/Hardener 1/PMMA, 3 days at 4 ◦C
4. Polymerization solution, 14-21 days at −20 ◦C.
The Technovit basic solution was de-stabilized by flowing the stabilized solution through a
column of approximately 160 g Al2O3. For polymerization, the samples were placed in 20 ml
polystyrene syringes and each filled with approximately 10 ml of freshly prepared Technovit
polymerization solution. The air was pushed out of the syringes, which were then closed with a
cap and sealed with parafilm to prevent the polymerizing samples from contact with air. The
fully polymerized histoblocks (figure 12) were cut out of the syringes and underwent microradio-
graphy and histology.
2.2.3.3 Microradiography
After the polymerization was completed, the histoblocks were placed in a microradiograph and
scanned at an accelerating voltage of 65 kV and 1 subscan. Resulting images were obtained as
analyze files and processed with the IMALYTICS Pre-clinical 2.0 software. The steps shown in
figure 13 were performed to evaluate the volume of newly formed mineralized tissue within the
defect regions.
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Figure 12: Methyl methacrylate embedded bones. The histoblocks were sagitally halved, polished and
sectioned for histology.
2.2.3.4 Histology
For histology, the polymerized histoblocks were sagitally cut in two halfs with a diamond saw.
After an additional polishing step with 800µm sandpaper, 7µm sagittal sections were cut with
a rotating microtome (size D blade, sample and blade wetted with 30 % ethanol), stretched in
70 % ethanol and pressed overnight on Superfrost Plus slides, sealed with a polyethylen film
at 50 ◦C, in a mounting press. Prior to staining, the histological sections were deplastizised
following the steps in table 8. Directly after deplastization, the Aqua dest. immersed sections
were stained with hematoxylin & eosin (HE) or Movat’s pentachrome (PC). Two sections cut
from the center of each defect were evaluated with HE staining for overview and PC staining
for a detailed analysis of the osteoid, mineralized and elastic compartments of the sections. The
staining precedures are described in table 9 and 10. The PC staining was conducted manually
and the HE staining was carried out by an autostainer. The PC stained histological slides
were evaluated qualitatively for the presence of connective and mineralized tissue, cartilage
and osteoid. HE stained histological slides were evaluated qualitatively and quantitatively by
pathologist Dr. med. Paul Kachel (Institute of Pathology, RWTH Aachen) for general signs of
chronic or acute inflammation or foreign body reaction, like the presence of inflammatory cells
(lymphocytes and granulocytes) or foreign body giant cells.
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The solutions for Movat’s PC staining were prepared as follows:
• Alcian blue
1 g Alcian blue powder in 99 ml of Aqua dest. + 1 ml of 1 % acetic acid, filtered through a
pleated filter
• Alkaline alcohol
10 ml of 25 % ammonia + 90 ml of 96 % ethanol
• Weigert’s hematoxylin
Mix both solution A and B in a ratio of 1:1 shortly before usage
• 5 % Phosphotungstic acid
10 g phoshotungstic acid hydrate powder in 200 ml of Aqua dest.
2.2.4 Statistical Analyses
Data analysis was performed using Graphpad Prism 6.0 software. Comparison between groups
was performed via one-way or two-way analysis of variance (ANOVA) models with Tukey’s
multiple comparison tests. Differences with p < 0.05 were considered statistically significant.
The data were obtained from independent samples (n ≥ 3) and are expressed as the mean ±
standard deviation or mean ± standard error of mean.
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Figure 13: Microradiographic evaluation of newly formed bone. Exemplary pictures of the 3D illustrated
data of each material are shown in step 1. The volume of newly formed bone was expressed as the ratio
of bone volume to original defect volume, as shown in step 2, 3 and 4.
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3 Results
3.1 Culture of human and ovine MSC
To improve the comparability of study outcomes by minimizing differences in isolation and
characterization of designated MSC populations, in 2005, the Mesenchymal and Tissue Stem Cell
Committee of the International Society for Cellular Therapy stated two position papers defining
the minimal criteria to characterize human MSC Dominici et al. [2006]Horwitz et al. [2005].
These criteria are commonly accepted by stem cells researchers worldwide. First, MSC must be
plastic-adherent when maintained in standard culture conditions. Second, MSC must express
CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79α or CD19
and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and
chondroblasts in vitro, when cultured in respective induction media Dominici et al. [2006]. For
characterizing ovine MSC, no such officially stated criteria exist. In previous studies, oMSC
were characterized like human MSC, but with inconsistency in the set of surface antigens. The
most frequently tested antigens for ovine MSC encomprise anti-human CD29, CD73, CD90, and
CD105 as well as anti-ovine CD44 and CD45 Rentsch et al. [2010]McCarty et al. [2009]Mrugala
et al. [2007], which were also investigated in this study .
3.1.1 Isolation and Expansion
After successful isolation, adherent cells could be observed under the microscope five to ten
days later. As depicted in figure 14, cells from both species showed a flat and spindle-shaped
morphology, which is typical for MSC. However, human MSC were almost double the size
of ovine, with an approximated average length of 100-200µm versus 50-100µm. Ovine MSC
concurrently formed larger colonies in comparison to human MSC. The doubling time (Td) for
MSC from both species was calculated with the formula:
Nt = N0 · expµ·t ⇒ Td = ln 2µ
where No is the initial number of cells, Nt is the number of cells after the time period t and
µ is the empirically determined growth rate [/day]. According to the growth curves of four
individual donors from passage 1 to 4, depicted in figure 14, doubling times were:
human MSC: Td = 10± 2.6 days
ovine MSC: Td = 4± 0.8 days.
In general, ovine MSC proliferated faster and reached the fourth passage earlier.
40
3 Results
Figure 14: (A) Light microscopic pictures of human and ovine MSC 9 days after isolation (passage 0).
MSC from both species showed the typical flat and spindle-shaped morphology. Human MSC were larger
than ovine and built smaller colonies. Exemplary picture of n = 5. (B) Expansion of human and ovine
MSC. Cumulative cell numbers of four individual donors from passage 1 to 4 are shown. Collectively,
ovine MSC proliferated faster than human MSC.
3.1.2 Surface Epitope Expression
Since there is no single surface epitope that characterizes MSC, a pattern of several different
epitopes is measured to prove their phenotype. The mean values ± SD from flow cytometric
data are listed in table 5. Exemplary images of the corresponding graphical results are shown in
figure 15. Human MSC homogenously expressed CD44, CD73, CD90 and CD105 and did not
express anti-human CD45 (and anti-ovine CD29). This expression pattern is in accordance with
published results for multipotent human MSC from Pittenger et al. Pittenger [1999].
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Table 5: Surface epitope expression of human and ovine MSC measured by flow cytometry [% positive
cells ± SD]
CD29+ CD44+ CD45+ CD73+ CD90+ CD105+
human MSC 0±0 96.0±4.1 0.75±1.0 99.26±0.5 94.75±4.4 81.75±6.2
Ovine MSC 0±0 94.5±3.7 12.5±13.2 56.5±39.0 38.25±34.7 52.5±34.5
The expression pattern of human MSC was reproducible and stable from passage 1 to 4. Ovine
MSC generally showed more fluctuation in the expression of surface markers, especially of anti-
ovine CD45. Deviate from expectations, anti-ovine CD45 was partially positive for 3 from 5
ovine MSC donors, resulting in an average of 12.5 % positive cells with a relatively large SD of
13.2 %. Collectively, more than 90 % of ovine MSC were positive for CD44, and 5 to 90 % were
positive for CD73, CD90 and CD105 (see table 5).
Figure 15: Exemplary graphs of surface epitope expression of human and ovine MSC analyzed with
flow cytometry. Red curves show fluorescence of isotype controls, blue curves show fluorescence of cells
stained with the antibody described above.
3.1.3 Osteogenic Differentiation
During osteogenic differentiation MSC secrete calcium phosphate, a major component of bone,
into the extracellular space. The degree of extracellular calcium accumulation was validated with
Alizarin red staining after 7, 14, 21 and 28 days. As shown in figure 16, calcium accumulations
started to become visible after 14 days of treatment with OIM for both cell types. This accu-
mulation further increased after 21 days and then reached a plateau until day 28. Notably, ovine
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Figure 16: Alizarin red stained human and ovine MSC after 7, 14, 21 and 28 days of treatment with
OIM or SCM. Red stained calcium accumulations were visible after 14 days of treatment with OIM and
increases to its maximum on day 21. Magnified section from ovine MSC shows an example of apoptotic
bodies, which frequently formed in the SCM condition between 21 and 28 days, the scale bar is 30 µm.
Exemplary pictures of n = 5.
MSC formed bulging edges (figure 16, bottom row) in cell culture wells when grown for 28 days
in SCM, and frequently formed apoptotic bodies after this time period (figure 16 bottom row,
magnified section). For both human and ovine MSC, no spontanous osteogenic differentiation
following culture in SCM was observed.
3.1.4 Adipogenic Differentiation
Adipocytes derive from mesodermic lineage and their production from MSC in vitro is required
for proving their multipotency. Human and ovine MSC were induced by treatment with adi-
pogenic induction media (IM) as described in chapter 2.1.6.3 to 2.1.6.5. Both cell types showed
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Figure 17: Oil red O stained human and ovine MSC after 7, 14 and 21 days of treatment with SCM
or the respective induction media (IM) described in chapter 2.1.6.3 to 2.1.6.5. Cells from both species
formed large lipid vacuoles after treatment with IM. At the same time, numerous small lipid vacuoles in
SCM treated control cells were observed, especially for ovine MSC. Exemplary pictures of n = 5.
numerous small lipid droplets in control conditions. However, only when cultured in IM, large
lipid filled vacuoles were observed as depicted in figure 17. Remarkably, ovine MSC did not
differentiate into adipocytes when induced with the protocol for human MSC Adamzyk et al.
[2013].
3.1.5 Chondrogenic Differentiation
Cartilage is a mesodermic tissue which is avascular, anerval and which consists of only one cell
type, the chondrocyte. Chondrocytes produce large amounts of extracellular matrix composed
of collagen fibers, proteoglycan, and elastin fibers. To promote chondrogenic differentiation,
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Figure 18: Toluidine blue stained paraffin sections of pellet cultured human and ovine MSC after 21 days
treatment with chondrogenic induction medium (CIM). The sample tissues were hyaline in appearence and
rich in dark blue stained extracellular matrix and proteoglycans (magnifications on the right). Exemplary
pictures of n = 3.
human and ovine MSC were centrifuged to produce a pellet and were treated with CIM. The
results of chondrogenic differentiation are shown in figure 18. Highly differentiated chondrones
containing chondrocytes were visible with a proteoglycan rich blue stained extracellular matrix,
after 21 days of treatment with CIM. Control pellets (not shown) cultured in SCM for 21 days
also revealed light blue stained extracellular matrix but the intensity in induced samples was
markedly higher. Furthermore, the sample tissue did not appear as highly organized and the
hyaline structure of chondrones and chondrocytes was not detectable.
3.2 In vitro Analyses
The biomaterials were investigated for their general cytocompatibility with MSC and their os-
teoconductivity. In general, biomaterials critically influence the proliferation and differentiation
of MSC in a positive or negative way. Therefore, the osteogenic differentiation of MSC on the
3D-scaffolds was first investigated with different in vitro assays prior to the in vivo assessment.
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3.2.1 Cytotoxicity and Viability
Cytotoxic effects of biomaterials on MSC in cell culture are an eliminatory criterion for possible
in vivo applications. The cytotoxicity was first assessed with live/dead staining, 24 h after cell-
seeding. As depicted in figure 19, viable cells (green fluorescent) were found on each material.
No or very few dead cells (red fluorescent) could be observed on all biomaterials. However, its
extraordinarily high red autofluorescence impaired the evaluation of dead cells on PEKK.
Figure 19: Live/dead staining of MSC on 3D-scaffolds. Viable cells are shown in green, lysed cells
are shown in red. Viable MSC got adherent and were homogenously distributed on each biomaterial.
No or very few dead cells were observed on the biomaterials. PEKK revealed a very prominent red
autofluorescence. Exemplary pictures of n = 3.
For a more extended cytotoxicity investigation, the cell membrane integrity assay was performed
subsequently. As shown in figure 20, no cytotoxic effect could be measured by lactate dehydro-
genase release over a period of 21 days from both cell types. Data points (not normalized) of
human MSC were very similar between TCPS and all 3D scaffolds. However, PDLLA showed
slightly increased values (' 20 units more) together with ovine MSC. No significant difference
could be observed in comparison to the TCPS control or the other 3D-scaffolds.
Cell adherence and metabolic activity are crucical factors for successfully delivering living MSC
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Figure 20: Cytotoxicity measurement via membrane integrity and lactate dehydrogenase release. Al-
though variation of ovine MSC was slightly increased for PDLLA, no significant cytotoxic effect of the
tested biomaterials could be observed (p > 0.05). Mean values ± SEM of n = 3.
into a critical-size bone defect. In this context, different initial cell densities and morphologies
were observed by live/dead staining on the materials after 24 h, as shown in figure 19. On
PEKK, fewer cells with roundish morphology were observed, while on PDLLA and both silk
types, stretched and spindle-shaped cell bodies aligned on the scaffold surfaces. As illustrated in
figure 21, both human and ovine MSC increased in metabolic activity during 21 days, except for
human MSC on PDLLA. In general, the metabolic activity of MSC from both species was lower
when cultured on the 3D-scaffolds in comparison to TCPS. In figure 21b, the bars represent
the area under the curve, which was calculated from the measurements shown in figure 21a.
This comparison allows for One-way-ANOVA to test statistically significant differences in the
metabolic activity between the conditions. Thereby, significantly lower metabolic activity of
human MSC on PDLLA and of ovine MSC on PEKK were detected. A fresh cell-seeded scaffold
was measured at each time point to avoid the measurement accumulative effects of the CellTiter-
Blue R© reagent.
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Figure 21: Viability measured over 21 days via metabolic activity. (A) All values were normalized to the
corresponding initial viability on day 1. No increase in metabolic activity of human MSC on PDLLA was
measured. Increasing viability, for both human and ovine MSC, was detected on all other biomaterials. To
perform a statistical analysis, the area under the curve was calculated (B). PDLLA showed a significantly
smaller area under the curve in combination with human MSC, while metabolic activity on PEKK was
significantly smaller in combination with ovine MSC. Mean values± SEM of n = 3, ∗p < 0.05.
Since it is crucial to homogenously cover the whole 3D-scaffold’s surface with MSC to provide
a good contact between the delivered and the body’s innate cells in bony defects in vivo, the
distribution of living cells on the 3D-scaffolds was visualized with the Typhoon fluorescence
scanner after live/dead staining, as depicted in figure 22. To distinguish green fluorescent cells
from the autofluorescence, cell-free scaffolds were scanned simultanously. A distinctly increased
fluorescence of the cell-seeded scaffolds was obatined, with a homogenous distribution on each
scaffold.
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Figure 22: Representative pictures of photographed and live/dead stained scaffolds, seeded with ovine
MSC and cultured for 21 days in SCM. The live/dead staining was detected with a fluorescence scanner.
PEKK and silk scaffolds showed green autofluorescence. Viable cells were homogenously distributed on
the scaffolds.
3.2.2 Alkaline Phosphatase Expression
In vivo, ALP is a hydrolase enzyme responsible for removing phosphate groups from nucleotides
and proteins at an alkaline pH [Orimo, 2010]. ALP is known to be increasingly expressed by
MSC with ongoing ostoegenic differentiation in vitro Schantz et al. [2003]Janicki et al. [2011].
The ALP expression measured from the p-nitrophenole production in the supernatant of the
cell-seeded scaffolds was increased at all time points in the OIM treated samples compared to
the SCM treated samples. As shown in figure 23, the highest ALP expression for both human
(1.26± 0.38) and ovine MSC (1.13± 0.06) was observed on PEKK after 21 days. Culture on silk
or silk + HA resulted in a substantially lower ALP expression compared to the other 3D-scaffolds
(max. 0.49± 0.28 for human and max. 0.52± 0.48 for ovine MSC).
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Figure 23: Alkaline phosphatase secretion of (A) human and (B) ovine MSC was measured colorimet-
rically from scaffold culture supernatant at day 7, 14 and 21. From each scaffold, the expression of
ALP following OIM culture was higher in comparison to SCM culture. PEKK revealed the highest ALP
activity of all biomaterials after 21 days in both human and ovine cultures. Mean values± SEM of n = 3,
∗p < 0.05, ∗∗p < 0.001.
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3.2.3 Alizarin Red Staining
The osteogenic differentiation was further examined with Alizarin red staining to visualize the
accumulation of calcium nodules indicative of advanced osteogenic differentiation Gentleman
et al. [2009]. As illustrated in figure 24a, the Alizarin red staining was strongly positive on
each of the OIM cultured scaffolds. However, PDLLA and both silk types revealed a high
background binding of Alizarin red to the cell-free scaffolds, which was additionally confirmed
by quantification of alizarin red, shown in figure 24b. Interestingly, on PDLLA and silk + HA,
a significantly increased red staining was not only observed from cells cultured in OIM but also
from cells cultured in SCM.
3.2.4 Quantitative Realtime PCR
In addition, the osteogenic differentiation was analyzed on the RNA level using relative quan-
tification of gene expression by realtime PCR. As shown in figure 25, the marker genes BMP2,
Runx2, and ALP were at least twofold up-regulated on TCPS, both for human and ovine MSC,
following a 21 day culture in OIM relative to SCM. Up-regulation of these marker genes on TCPS
served as control and confirmed substantiated osteogenic differentiation in the two-dimensional
control. The osteogenic marker genes were also up-regulated in most of the biomaterials. How-
ever, human MSC revealed a considerably lower up-regulation in comparison to ovine MSC (max.
5.47 ± 2.53 in comparison to 74.62 ± 50.86) and a lower variation, expressed as the standard
error of mean (SEM). No significant differences between the biomaterials were detected.
3.2.5 Alexa488-labeled Fetuin-A Staining
As a proof of principle, Alexa Fluor 488-labeled fetuin-A staining was performed for human
and ovine MSC on TCPS, as well as single samples of human MSC on PEKK and PDLLA.
As the TCPS control indicates, fetuin-A staining was specific for OIM cultured cells, of both
human (figure 26) and ovine (not shown) origin. While Alizarin red stained unsprecific calcium
accumulations, fetuin-A specifically bound calcium phosphate and thus provided a more specific
indicator of mineralized osteogenic cells.
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Figure 24: Alizarin red staining of MSC cultured on 3D scaffolds for 21 days. Red stained calcium
accumulates indicated osteogenic differentiation. (A) Representative photographs of ovine MSC showing
a strong positive staining on each scaffold after culture in OIM. PDLLA and silk + HA also showed
positive staining of SCM cultured cells. (B) Quantification of Alizarin red revealed significantly increased
staining for OIM on PEKK and silk in comparison to their SCM cultured counterparts. PDLLA and silk
+ HA both revealed an increased background staining. Mean values±SEM of n = 3, ∗p < 0.05.
52
3 Results
Figure 25: Osteogenic marker gene expression of MSC for Runx2, BMP2, and ALP was calculated
relative to housekeeping gene of (A) human MSC (GAPDH) or (B) ovine MSC (β2-microglobuline), after
21 days of culture on 3D scaffolds in OIM or SCM. Mean values± SEM of n = 3. No significant differences
were observed between the biomaterials (p > 0.05).
3.3 In Vivo Analyses
All sheep survived and tolerated surgery. After opening the cranial vault, abscess formation
around the three silk + HA implants in one animal was observed. Additionally, one cell-free
PDLLA scaffold could not be recovered from the cranium and was lost for evaluation.
3.3.1 Microradiography
To recieve information about the overall volume of mineralized tissue within the defect region,
microradiography was performed with each defect explant after PMMA embedding. A coronal
view on exemplary microradiographic images is presented in figure 27a. New bone tissue invaded
all defects ventrally from the side of the dura mater and horizontally from the adjacent bone.
Five of the ten empty defects showed a complete defect bridging with mineralized tissue (not
shown) and therefore were considered to be subcritical-size. However, no biomaterial showed
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Figure 26: Exemplary staining of human MSC seeded on PDLLA and PEKK scaffolds, which were
cultured in SCM or OIM for 21 days, with Alexa Fluor 488-labeled fetuin-A (green) and Dapi (blue).
Selectively, calcium phosphates of OIM treated cells bound green-fluorescent fetuin-A.
a complete horizontal bony bridging of the defect area. In case of PEKK, new bone tissue
formed in the remianing available space of the interconnected channels with seamless transition
to the adjacent bone. PDLLA, silk and silk + HA treated defects revealed bone formation
mostly at the ventral side from the side of the dura mater. The quantified ratios between bone
and defect volume are depicted as bar graphs in figure 27b and listed as mean values ± SEM
in table 6. Empty defects revealed an average bone volume of 0.48 ± 0.05. Untreated cortical
bone from the calvaria showed significantly higher volumes (0.81 ± 0.02) in comparison to all
empty (p < 0.01) and biomaterial treated (p < 0.05) groups. The largest ratio of newly formed
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Table 6: Microradiography: Results are expressed as mean ± SEM of bone volume per defect volume
from n=4-5
Control Scaffold +MSC +MSC diff.
Empty 0.48± 0.05
Cortical Bone 0.82± 0.02
PDLLA 0.37± 0.05 0.30± 0.07 0.30± 0.05
PEKK 0.50± 0.09 045± 0.05 0.46± 0.07
Silk 0.14± 0.03 0.21± 0.04 0.18± 0.03
Silk + HA 0.52± 0.10 0.24± 0.08 0.30± 0.20
bone per defect from the biomaterial treated groups was observed in cell-free scaffolds of PEKK
(0.50± 0.09) and silk + HA (0.52± 0.11). The least volume of newly formed bone was observed
in the silk (0.14±0.03) treated defects. No significant differences between cell-free, MSC-seeded
or pre-differentiated MSC-seeded scaffolds (scaffold; +MSC; +MSC. diff) were observed in any
biomaterial treated group, but a tendency towards higher bone formation from cell-free scaffolds
for PDLLA, PEKK, and silk + HA, was measured. Alone, unmodified silk produced a different
tendency. Here silk scaffolds +MSC showed slightly increased ratios of new bone formation
(0.14± 0.03 versus 0.21± 0.04).
3.3.2 Histology
For a detailed and comprehensive evaluation of the defect healing, histological sections were pro-
duced from each sample and stained with HE or Movat’s PC. Notably, during methyl methacry-
late embedding (chapter 2.2.3.2), the PDLLA scaffold had dissolved and only remnants of the
original biomaterial were observed in the histologic stainings.
3.3.2.1 Hematoxylin and Eosin Staining
The HE staining provided a general overview of the histological sections, with mineralized bone
tissue visible in dark red and connective or fibrotic tissue visible in light pink. The biomaterials
appeared grey (PEKK), yellowish (PDLLA) and bright pink (silks). Figure 28 shows exemplary
macroscopic and microscopic views of the HE stained samples. For histomorphometric anlysis,
the presence of fibrosis, lymphocytes, giant foreign body cells (GFBC) and bone was evaluated
by morphological appearence. The samples were scored semi-quantitatively with points from
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Figure 27: (A) Exemplary microradiographic views obtained from sheep calvarial defects after 12 weeks
of implantation. Empty defects and fully mature cortical bone served as controls. New bone grew from
the side of the dura mater (ventral) and adjacent bone (horizontal) towards the center of the original
defect. Note the radioluscency of all scaffolds in microradiography, only mineralized structures are visible.
Figure continues on next page.
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Figure 27: continued. (B) Quantification of microradiographic images expressed as the volume of
newly formed bone per volume of original defect. Cortical bone showed significantly higher bone volume
compared to all empty (**p< 0.01) and biomaterial treated (*p< 0.05, not shown) defect groups. No
significant differences between cell-free scaffold, +MSC and +MSC diff. treated defects were detected
(*p> 0.05). Mean values ± SEM of n=4-5.
0-3, with 0 meaning no tissue/cells present to 3 highest tissue/cell accumulation of all samples
present. The results are shown as bar graphs in figure 28, and are listed in table 7.
Collectively, new bone was localized in all samples and empty controls. In accordance with
microradiographic findings, the bone ingrowth was observed to start from the adjacent bones
and the side of the dura mater towards the defect center. Newly formed osteoid, secreted by
osteoblasts as a structural basis for trabeculae forming, was best recognized in the empty controls
(figure 28a). Lymphocytes were identified from the accumulation of dark nuclei surrounded
by few cytoplasm. Both, silk and silk + HA exhibited a pronounced lymphocytic immune
reaction (Lymph, 1.67 ± 0.33 and 2.75 ± 0.25), which was especially present in close contact
with the silk fibers (figure 28c-d). Fibrosis was identified from the light pink collagenous fibers,
which were most of the time highly oriented and which were interfused with flat nuclei of
fibroblasts (figure 28a-b and d-e). The most distinctive fibrosis from all samples was found
in silk or silk + HA treated defects (2.25 ± 0.25 and 2.00 ± 0.00). Giant foreign body cells
were mostly observed in close contact to the PEKK scaffold (GFBC, 2.8 ± 0.20) and were
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Table 7: Histomorphometry of explants. All defect groups were evaluated with a histological score from
0 (no appearence) to 3 (strongest appearence of all samples), mean values ± SEM from n=4-5 are listed
Lymph GFBC Fibrosis New Bone
Empty 0.50± 0.17 0.00± 0.00 1.30± 0.40 2.20± 0.36
PDLLA
Scaffold 0.75± 0.25 0.50± 0.29 0.75± 0.25 0.50± 0.29
+MSC 0.75± 0.25 1.25± 0.25 0.75± 0.25 0.50± 0.29
+MSc diff. 1.00± 0.00 1.25± 0.25 0.75± 0.25 1.00± 0.00
PEKK
Scaffold 0.80± 0.20 2.80± 0.20 1.60± 0.25 2.40± 0.5
+MSC 1.20± 0.20 2.60± 0.25 1.60± 0.25 2.4± 0.25
+MSC diff. 0.80± 0.37 2.6± 0.24 1.80± 0.37 2.40± 0.40
Silk
Scaffold 2.75± 0.25 2.00± 0.40 2.25± 0.25 1.25± 0.25
+MSC 2.75± 0.25 1.75± 0.25 2.5± 0.29 1.25± 0.25
+MSc diff. 2.75± 0.25 2.00± 0.41 2.75± 0.25 1.00± 0.41
Silk + HA
Scaffold 1.67± 0.33 2.33± 0.33 2.00± 0.00 2.33± 0.33
+MSC 1.50± 0.50 2.00± 0.00 2.50± 0.50 2.00± 1.00
+MSc diff. 2.00± 0.58 2.00± 0.00 2.33± 0.33 2.00± 0.58
identified from the large and polynuclear cell body (figure 28c). PDLLA in contrast, revealed
only moderate levels of fibrosis, lymphocytes and giant foreign body cells in comparison to the
other scaffolds (0.5±0.30 to 0.75±0.25). Since little or no granulocytes were present in all samples
(not shown), this cell type was excluded from the histological score. All biomaterials were
surrounded from a capsule of loose or connective tissue with secreting fibroblasts visible between
the collagenous fibers (figure 28b-d, macroscopic and microscopic views). For silk and silk + HA
scaffolds, a tendency towards increased fibrosis and decreased bone tissue formation between
cell-free and + MSC or + MSC diff. samples was observed (table 7 and figure 28). However, less
giant foreign body cells concurrently were observed in these samples, compared to their cell-free
counterparts. In contrast, on PDLLA, more giant foreign body cells from + MSC and + MSC
diff. samples (1.25 ± 0.25 both) were observed compared to cell-free scaffolds (0.5 ± 0.30). In
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accordance with microradiographic examination, on average no significant difference (p > 0.05)
in the newly formed bone volume between the cell-free (scaffold), the MSC-seeded (+MSC)
or the osteogenically pre-differentiated MSC-seeded (+MSC diff.) samples were observed by
histomorphometry. Likewise, no significant differences were found in fibrosis, giant foreign body
cells and lymphocytes.
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Figure 28: (A-B) Histological sections obtained from sheep calvarial defecs after 12 weeks of implantation,
stained with HE. Figure continues on next page.
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Figure 28: Continued. (C-D) Histological sections obtained from sheep calvarial defecs after 12 weeks
of implantation, stained with HE. Figure continues on next page.
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Figure 28: Continued. (E) Histological section obtained from sheep calvarial defecs after 12 weeks
of implantation, stained with HE. (F) Histomorphometry for the tissue/cell types scored from 0 (no
appearence) to 3 (strongest appearence of all samples). Lymphocytes (Lymph), giant foreign body cells
(GFBC), fibrosis and new bone tissue were evaluated. Mean values ± SEM from n=4-5.
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3.3.2.2 Movat’s Pentachrome Staining
Movats PC staining provided a more detailed view of the mineralized and elastic parts of the
newly formed tissue and its ossification stages. In figure 29, exemplary histological sections
from all biomaterial treated groups after Movats PC staining are shown. Here, mature bone
appeared dark yellow and connective tissue or collagenous fibers appeared light yellow to light
green. Newly formed osteoid, which represents the active stage of new bone accumulation, ap-
peared red, cartilage was bright green and nuclei were stained in dark brown. The transition
from cartilageous into mineralized tissue was observed in all samples and is shown in detail
in figure 29a from a PEKK treated defect. This transition is characteristic for endochondral
ossification [Rentsch et al., 2014]. Osteoblasts and osteoclasts were found at the interface of
fully mature bone and remodeled cartilage or stromal cells. In the mineralized matrix, osteo-
cytes and remnants of cartilage were found. As demonstrated in figure 29b, the tendency of
PDLLA to show an increased formation of fully mature bone in +MSC diff. treated samples
was in accordance with microradiography. The inclusion of PDLLA scaffolds with a fibrotic
capsule was very well visible in PC stained sections. Only PEKK showed a direct contact of
biomaterial with mineralized bone tissue (osseointegration), as shown in figure 29c. However, no
differences in osseointegration between cell-free and MSC-seeded PEKK scaffolds were observed.
Furthermore, the tendency towards increased fibrotic tissue formation and lymphocytic immune
reaction in both silk types was confirmed, as depicted in figures 29d-e. The increased formation
of fully mineralized bone tissue in the HA modified silk scaffolds compared to unmodified silk,
in accordance with microradiography, was also confirmed by Movat’s PC staining (figure 29e).
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Figure 29: (A) Overview of endochondral ossification taking place in all sheep calvarial defects after 12
weeks of implantation. Different cellular and structural components of the remodeling from cartilage to
bone are shown exemplarily from a PEKK treated defect. (B) Overview of histological sections stained
with Movat’s PC. Figure continues on next page.
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Figure 29: continued.(C-D) Overview of histological sections stained with Movat’s PC. Figure continues
on next page.
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Figure 29: Continued. (E) Overview of histological sections stained with Movat’s PC.
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4 Discussion
The repair of critical-size defects is a major goal in reconstructive surgery. Due to high mor-
bidity associated with autologous bone graft harvesting, current research has largely focused
on alloplastic substitutes [Kinoshita & Maeda, 2013; Tevlin et al., 2014]. Although a number
of alloplastic material-based approaches have been developed and used with variable success
to date, none has proven ideal so far [Brydone et al., 2010; Oryan et al., 2014]. Given these
problems, a cell-based therapeutic approach is desireable to increase the success of alloplastic
materials and the formation of new bone within critical-size defects [Oryan et al., 2014; Rosset
et al., 2014].
Within the current study MSC from men and sheep were isolated, expanded and characterized
by phenotype and function prior to seeding on 3D-scaffolds made of PDLLA, PEKK, silk and
silk + HA. The cytotoxicity, proliferation and osteogenic differentiation on these 3D-scaffolds
were investigated with in vitro assays and cell-free or MSC-seeded scaffolds were implanted in
vivo in calvarial defects in sheep. The ultimate goal was to investigate the effect of MSC-seeding
on bone formation within the calvarial defects. The main results of this study were:
1. Ovine MSC were successfully isolated, expanded and differentiated into cells of osteogenic,
adipogenic and chondrogenic lineage.
2. MSC from both human and ovine origin homogenously attached on 3D scaffolds made of
PDLLA, PEKK and silk or silk + HA. Osteogenic differentiation was successfully induced
by culture in OIM for 21 days.
3. Unmodified silk but not silk + HA scaffolds evoked a distinct inflammatory immune reac-
tion when implanted into sheep calvarial defects. PEKK evoked a foreign body reaction.
All biomaterials were, at least partly, encapsulated with fibrous tissue.
4. The largest volume of newly formed bone from the scaffold-treated defects was observed
in cell-free PEKK and silk + HA implants. The volume of newly formed bone was not
increased by MSC-seeding in comparison to cell-free scaffolds.
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4.1 Isolation, Expansion and Characterization of Human and Ovine MSC
Due to their availability, low cost, ease of handling and ethical acceptance, sheep are a con-
venient large-animal model in orthopaedic surgery [O’Loughlin, 2008; Potes, 2008]. Although
characterization studies on ovine MSC are published in a couple of papers [Lyahyai et al., 2012;
McCarty et al., 2009; Mrugala et al., 2007; Rentsch et al., 2010; Zannettino et al., 2010], there is
no consistency in the isolation procedure, use of expansion media, surface epitope analyses and
differentiation protocols. Thus, considerable variances in the cultured ovine MSC population,
and their performance in tissue engineering studies are presumed. For human MSC, the Mes-
enchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy
proposed the introduction of a standardization for the phenotypic characterization, as stated
in their position papers of Horwitz et al. [2005] and Dominici et al. [2006]. Although donor
variances have been reported, differentiation of human MSC into adipocytes, osteoblasts and
chondrocytes is nowadays standardized according to protocols originally published by Pittenger
[1999]. In contrast, no such standardization is available for ovine MSC to date. Based on preced-
ing experiments for the current study we decided to culture ovine MSC in the culture medium for
human MSC (see chapter 2.1.6.1), containing 2 % FCS and 10 ng/ml EGF, as we found superior
proliferation and differentiation of ovine MSC in this medium compated to another standard
medium composed of DMEM containing 10 % FCS [Adamzyk et al., 2013].
The faster proliferation and smaller size of ovine MSC compared to human MSC is in accordance
with literature and was observed independently from the culture media [Mrugala et al., 2007;
Rentsch et al., 2010]. Mrugala 2007 hypothezised that longer telomeres or the expression of
embryonic genes, although not systematically investigated, might be the decisive factors. The
differentiation potential has been described heterogeneously in literature. A recently published
study from Kalaszczynska et al. [2013] stated that osteogenic differentiation of ovine MSC was
not successful by addition of β-glycerophosphate and L-ascorbic acid (standard protocol) to
their DMEM-based culture medium, only when NaH2PO4 was added to the culture, a success-
ful osteogenic differentiation was observed by Alizarin red staining and ALP expression. In
contrast, a successful osteogenic induction by following the standard protocol for human MSC
(see chapter 2.1.6.2), with beta-glycerophosphate and L-ascorbic acid addition, was obtained
in our study. However, strong donor-dependent variations in differentiation were observed, as
published in Adamzyk et al. [2013]. For adipogenic and chondrogenic differentiation, the stan-
dard protocols published by Pittenger [1999] did not lead to the desired state of differentiation.
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Therefore, varying protocols as published in Rentsch et al. [2010] and McCarty et al. [2009]
were applied. We also observed a tendency of oMSC to spontanously form lipid droplets when
cultured in SCM. This might be due to their general physiological metabolism and change from
red bone marrow into a yellow fatty bone marrow in long bones during lifetime [Lepperdinger,
2011; Morelli et al., 2015].
Taken together, we observed larger donor variations from ovine MSC, concerning surface epi-
tope measurements and differentiation in comparison to human MSC cultures. Populations of
ovine and human MSC were homogenous in morphology (figure 14), however, there may have
been differences in their differentiation or proliferation potential deriving from more or less po-
tent sub-populations [Neuhuber et al., 2008; Pevsner-Fischer et al., 2011; Phinney et al., 1999].
Pre-selection of specific cell types, which exhibit surface antigens known to coincide with MSC
subpopulations (STRO-1, CD271), has been described for human [Cuthbert et al., 2015; Gron-
thos & Simmons, 1995] and also for ovine MSC [Zannettino et al., 2010]. The pre-selection
leads to more functionally homogenous populations of MSC. Alternatively, we suggest that a
pre-selection method via binding of fluorescently-labeled galectin, as published in Kupper et al.
Kupper et al. [2013] might also be feasible.
4.2 In vitro analysis
4.2.1 Attachment and Proliferation of MSC on 3D-scaffolds
The basic requirement for bone tissue engineering is an appropriate cell source and a biocom-
patible scaffold conductive to cell attachment and maintenance of cell function [Arvidson et al.,
2011; Oreffo & Triffitt, 1999; Punet et al., 2013]. In this study, human and ovine MSC attached
homogenously on 3D-scaffolds of PDLLA, PEKK, silk and silk + HA, after dynamic cell seeding
(chapter 2.2.2.1).Thereby, the first and crucial step of delivering cells via the scaffold into the
defect side was successfully achieved. In case of PDLLA, silk or silk + HA, cells were evenly
distributed over the surface but not on the inside. In case of PEKK, cells were distributed within
the interconnected channels as shown by the fluorescence scan of live/dead staining (figure 19).
When examined in more detail, the live/dead staining revealed different densities of initially ad-
herent cells. As expected, the cell density was lower on the 3D-scaffolds in comparison to TCPS,
because the 3D structure of the materials increased the available surface of the cells. The lowest
initial cell density was found on PEKK. PEKK is known as a bio-inert and hydrophobic material
[American Society for Testing and Materials, 2012]. Hydrophilic or negatively charged surfaces
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are known to be superior for cell attachment, due to increased protein adsorption at the bio-
material surface [Keselowsky et al., 2005; Murphy & Mooney, 2002]. The biomaterial interface,
which is presented to living cells is further determined by the concentration and conformation of
attached proteins [Matsui et al., 2015; Portugal et al., 2014]. Thus, tere is optimal cell adhesion
to moderately hydrophilic and positively charged substrates, because cell adhesion-mediating
molecules like vitronectin or fibronectin adsorb in an advantageous geometrical conformation,
which makes specific amino acid sequences accessible to cell adhesion receptors, the integrins
[Bacakova et al., 2011; Mei et al., 2010]. The most common ligand that promotes cell adhesion
is the tripeptide RGD, which binds integrins [Gooding et al., 2014; Qiu et al., 2003; Ruoslahti,
1996]. The highest density of attached cells was found on silk + HA, followed by unmodified
silk. In general, silk fibroin scaffolds (from Bombyx mori cocoons) have been shown to be an
attractive substrate for MSC attachment, probably due to available RGD motifs on the surface
[Chen et al., 2003; Sofia et al., 2001; Wang et al., 2006]. This finding is of importance because
the cell-surface interactions influence the cellular response and thus the rate and quality of new
bone formation [Kinoshita & Maeda, 2013].
Similar to cell attachment, proliferation is another basic cell behavior, which is critically influ-
enced by biomaterials [Neuss et al., 2008]. The MSC seeded on scaffolds made of PEKK and
PDLLA revealed lower metabolic activities during 21 days in comparison to silk + HA. Thus,
the increased cell attachment and metabolic activity of both, human and ovine MSC, on un-
modified silk and silk + HA scaffolds, which was demonstrated here, might be accounted for
an enhanced adsorption of extracellular matrix proteins [Murphy et al., 2005], too. Similarly,
Murphy et al. demonstrated that hydroxyapatite-loaded, bone-like films supported the adsorp-
tion of fibronectin, which is a determinant of cell attachment and proliferation in vitro [Murphy
et al., 2005].
Importantly, the scaffolds empolyed here differed in their substrate dependent characteristics,
because varying bulk materials and architectures were chosen. This circumstance makes it dif-
ficult to see the determining factors that have led to variations in cell attachment and function.
Overall, the currently known factors which influence cell attachment and function in vitro are the
scaffold’s porosity, pore size and architecture (fiber diameter, interconnecting channels)[Costello
et al., 2010; Murphy et al., 2013], the rigidity (elastic modulus)[Babis & Soucacos, 2005; En-
gler et al., 2006], and the surface chemistry (hydrophilic or hydrophobic, positively/negatively
charged or uncharged)[Gooding et al., 2014; Kinoshita & Maeda, 2013]. Nonetheless, the molec-
ular mechanisms modulating these substrate-dependent cellular activities remain poorly under-
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stood. As a consequence, there is a lack of fundamental understanding, which still hinders the
progresss in development of synthetic materials that are designed to provide all desired cellular
responses [Keselowsky et al., 2005].
4.2.2 Osteogenic Differentiation
As shown by the ALP expression (figure 23), Alizarin red staining (figure 24), and realtime PCR
(figure 25), a successful osteogenic differentiation of human and ovine MSC was achieved for
each scaffold, following the differentiation protocol originally published by Pittenger [1999].
In comparison to the other scaffolds, an increased Alizarin red staining of SCM cultured cells
on PDLLA and silk + HA was observed, which might indicate a spontaneous differentiation
of MSC on the 3D-scaffolds of PDLLA and silk + HA. However, no increased ALP expres-
sion in SCM culture from these scaffolds (figure 24) was observed and the SCM gene-expression
levels from these donors were on average not increased in comparison to TCPS (not shown).
Therefore it is possible that the increased Alizarin red staining in SCM culture derived from
the high background staining, which was also observed in combination with these scaffolds
(figure 24a-b). However, for a final and more detailed evaluation of a possible spontaneous os-
teogenic differentiation, systematic conduction of immunofluorescence staining for proteins of
the osteogenic differentiation pathway like osteocalcin or osteoprotegerin and fetuin-A stain-
ing for calcium phosphate accumulation, in combination with comprehensive gene expression
analysis of at least three further donors would be necessary. The differential results obtained
by Alizarin red staining in this study clearly demonstrated the necessity of performing more
than only one method to reliably analyze the osteogenic differentiation, ideally on the genetic,
protein expression and extracellular calcium phosphate accumulation level. Alexa Fluor 488-
labeled fetuin-A stained the precipitated calcium phosphate and therefore successfully broadens
the range of staining methods for osteogenic differentiation. For better optical imaging of future
investigations, however, confocal microscopy is recommended for 3D-scaffolds in order to obtain
more precise images of the dispersion of fetuin-A binding in the different focus planes.
The overall best results for osteogenic differentiation were obtained from PEKK and silk + HA
scaffolds. Here, ALP expression, Alizarin red staining and osteogenic gene-expression showed
continuously highest values. Various studies have demonstrated the role of matrix elasticity on
osteogenic differentiation of MSC [Engler et al., 2006; Hao et al., 2015; Vincent et al., 2013]. In
2006, Engler et al. demonstrated that soft matrices that mimic brain support the neurogenic,
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stiffer matrices that mimic muscle support the myogenic, and comparatively rigid matrices that
mimic collagenous bone support the osteogenic fate [Engler et al., 2006]. PEKK has an elastic
modulus (5 GPa) which is near the range of that of bone (18 GPa) [Kurtz & Devine, 2007;
Moore et al., 1997]. Therefore, matrix elasticity might have positively influenced the osteogenic
differentiation in PEKK scaffolds. In comparison, titanium possesses an elastic modulus of
100 GaP [Lu et al., 2015], and PDLLA possesses one of only 2.8 GPa [Rafael A. Auras, Loong-
Tak Lim, Susan E. M. Selke, Hideto Tsuji, 2013]. The hydroxyapatite enforced silk scaffolds
might have benefited from the same effect of matrix stiffness. Although the elastic modulus of silk
+ HA is not known, compared to the unmodified silk scaffolds, silk + HA was less compressible
and stiffer. Furthermore, hydroxyapatite crystals, which were presented at the scaffold surface
in contact to MSC, have been shown to positively influence osteogenic differentiation [Hu et al.,
2014; Panda et al., 2014; Wei et al., 2011].
4.3 In vivo analysis
Results from in vitro studies can be difficult to extrapolate to the in vivo situation. For this
reason the use of animal models is often an essential step in the testing of bone implants prior to
clinical use in humans [Pearce et al., 2007]. In our study, ten sheep were employed to investigate
the performance of MSC-seeded biomaterials on calvarial bone regeneration in vivo.
4.3.1 Animal Model, Surgery and Sample Preparation
In orthopaedic research, sheep are a well accepted model for in vivo studies [Potes, 2008]. They
possess a body weight, size and bone structure comparable to that of adult humans, they are
readily available and easy to handle [O’Loughlin, 2008; Pearce et al., 2007]. The animal model,
including defect placement and size in this study was adapted from Xing et al. [2013], who
created critical-size defects of 1 cm diameter in the frontal bone of sheep calvaria for testing of
nanoparticle coated implants. These defects were not bridged with mineralized tissue (critical-
size) after a period of as long as 24 weeks. In the current study, in contrast, five of the ten defects
were bridged with mineralized tissue after only 12 weeks. A possible reason for this difference
might be the breed and age of the sheep. In Xing’s study, the breed had not been mentioned,
but certainly our sheep were of considerable younger age (6-year old vs. 1-year old). Pearce et
al. reported that the age of experimental animals does not only affect normal bone turnover but
may also affect the bone response in relation to implant materials [Pearce et al., 2007]. Similarly,
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Martini et al. [2001] reported that the critical defect size in each animal model is related to many
factors, such as species, breed, age, or skeletal site. The dimensions of a critical size defect in
bone do not seemingly translate simply across models, nor to humans, nor across different bone
defect sites, e.g., cranial to long bone [Auer et al., 2007]. As a consequence, studies employing
cirical-size defects in general should include preliminary testing of the critical-size healing during
the desired time period prior to conducting the main experiments, because the outcome of the
defect creation might be unpredictable otherwise.
4.3.2 Immune Response to 3D-Scaffolds
All materials when implanted into living tissue initiate an inflammatory immune response re-
flecting the first steps of tissue repair [Franz et al., 2011]. The inflammatory response is induced
by inductive factors, like the cell damage induced by biomaterial implant surgery [Boehler et al.,
2011]. Here, nanoseconds after the first contact with tissue, proteins adsorb to the biomaterial
surface. This layer of proteins then activates the coagulation cascade, complement system, and
immune cells of the body, which results in the formation of a transient provisional matrix and
the onset of the inflammatory response [Franz et al., 2011; Gorbet & Sefton, 2004; Wilson et al.,
2005]. Subsequently, the acute and chronic inflammation occur in a sequential order.
Acute inflammation is initiated by macrophage release of cytokines and chemokines that cause
increased movement of leukocytes from the intravascular space directly into the injured tissues
[Lin et al., 2014]. This process lasts only from minutes to days, depending on the extent of injury.
Subsequent release of macrophage-derived growth factors leads to the ingress of fibroblasts, MSC
and cells capable of neovascularization. This granulation tissue encapsulates the biomaterial
implant in a fibrous layer [Anderson & McNally, 2011; Lin et al., 2014]. Chronic inflammation
develops as inflammatory stimuli persist at the implant site with macrophages representing
the driving force in perpetuating immune responses [Hamilton, 2003]. Macrophages release
enzymes important for tissue reorganization and cytokines inducing migration and proliferation
of fibroblasts. They attempt to remove and degrade biomaterial particles by phagocytosis, but
if the implant or byproducts are large, macrophages undergo cell fusion to form multinucleated
GFBC (frustrated phagocytosis) [Anderson et al., 2008; Lin et al., 2014]. Larger foreign bodies
are engulfed by GFBC which secrete reactive oxygen species and nitrogen radicals, proteinases
and other lysosomal enzymes directly [Anderson et al., 2008]. They try to encapsulate the
biomaterial to resolve the acute inflammatory response. In case of PEKK, despite the low
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lymphocytic immune reaction, numerous GFBCs were observed around the implants. Although
it performed best in terms of volume of newly formed bone and osseointegration, the foreign
body reaction caused by PEKK poses a risk for long-term implantable devices, like it is with
PEKK, because foreign body reaction frequently leads to encapsulation and failure of bone
substitutes [Trindade et al., 2014].
GFBCs, macrophages and lymphocytes are indicative of the chronic immune response. The silk
implants investigated in this study showed increased numbers lymphocytes around the mem-
brane and the fibers (figure 28d-e). Bombyx mori silk fibers have been the primary silk-like
material used particularly as sutures in biomedical applications [Altman et al., 2003]. Although
used for decades, inflammatory immune reactions, including allergic reactions, against conven-
tionally produced bombyx mori silk (fibroin) have been reported before, e.g. after nerve ligation
operation and tracheal anastomosis in rabbits, as well as after ocular cataract surgery in adult
human patients, skin tests and neurosurgery in three pediatric patients, as reviewed in Altman
et al. [2003]. However, it is now clear that the sericin glue-like proteins were the major cause
of inflammatory and hypersensitivity reactions to silk. When sericin was removed, the biolog-
ical responses to the core fibroin fibers appeared to be comparable to most other commonly
used biomaterials [Wang et al., 2006]. In contrast, in the current study, novel silk scaffolds of
naturally sericin-free silk were employed, which rules out any adverse effects caused by sericin.
However, under these circumstances, no prior in vivo experiments or long-term experience were
published with this type of silk. In experiments of our group, similar silk scaffolds (modified with
hepatocyte growth factor, produced by Spintec-Engineering), also revealed a moderate chronic
inflammatory reaction when implanted subcutaneously into mice for three weeks [van de Kamp
et al., 2015]. Lymphocyte and macrophage interactions are known to be differentially influenced
by the material surface chemistry [Anderson & McNally, 2011; Ziats et al., 1988]. Although
not investigated systematically, fibroin degradation products or remnants from the production
process might be responsible for an altered surface chemistry which then in turn might have
caused severe immunogenic responses against the silk scaffolds in our study. Importantly, Franz
et al. [2011] concluded that the key for long-term survival and function of biomaterials is that
they do not elicit a detrimental immune response but lead to tissue regeneration and formation
of a stable interface.
In PDLLA scaffolds, the overall lowest immune response in terms of lymphocytes, GFBCs and
fibrotic tissue was observed. Indeed, a tendency towards increased bone formation was observed
in the pre-differentiated MSC treated PDLLA scaffolds (figure 28 and table 7), although not
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significant. As the chronic inflammation process hinders full tissue regeneration we hypothezise
that the comparably low immune response observed from PDLLA might have led to the suc-
cessful increase in bone formation following MSC seeding in this study.
4.3.3 New Bone Formation
The bone defects started to heal from the ventral side of the hard cerebral membrane, the dura
mater. It is well known that the dura mater plays a significant role in the healing of calvarial
defects [Greenwald et al., 2000a,b; Spector et al., 2002]. The dura mater appears to be both
the primary source of osteogenic cells and the source of osteoinductive factors during calvarial
wound healing [Cooper et al., 2010; Gosain et al., 2003; Wang & Glimcher, 1999]. Therefore,
it is of importance to take care not to damage the dura, when creating the calvarial defects by
drilling.
The majority of studies on bone tissue engineering report an increased new bone formation af-
ter implantation of autologous or xenogenic MSC transplantation together with scaffolds [Chen
et al., 2007; Giannoni et al., 2008; Gosain et al., 2005; Koob et al., 2011; Manassero et al., 2013;
Petite et al., 2000; Shang et al., 2001; Wang et al., 2015, 2014; Xing et al., 2013]. Remarkably,
these studies all employed varying animal models (sheep, dog, rat, mouse, rabbit) and bioma-
terials (coral, calcium phosphate cement, chitosan/silk/collagen, hydroxyapatite, collagen, beta
tricalcium phosphate, PLGA). To the best of our knowledge, no comparable study has been con-
ducted so far employing PDLLA, PEKK, silk or silk + HA in combination with autologous ovine
MSC for enhanced bone regeneration. The current hypothesis explaining the beneficial effect of
MSC is that they differentiate themselves into chondrocytes or secrete a number of factors that
can influence nearby endothelial cells and osteoblasts, including VEGF, angiopoietin (Ang-1),
basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF) and insulin-like
growth factor-1 (IGF-1), which induce angiogenesis and bone formation [Knight & Hankenson,
2013; Roux et al., 2015]. The cellular production of osteogenic and angiogenic factors plays a key
role in intercellular communication within bone tissue. It has also been reported that co-culture
of endothelial and mesenchymal progenitor cells leads to an increased osteogenic differentiation
in vitro [The´baud et al., 2012], which is in accordance with experiments from our group [Bienert
et al., 2015].
In the current study, we did not observe a beneficial effect on the volume or quality of newly
formed bone by autologous MSC-seeding. In the light of the former mentioned studies, the
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lack of positive effect from MSC in our study is surprising, however, it is not unprecedented.
Haberstroh et al. [2010] found similar results, when scaffolds of PLGA, tricalciumphosphate-
chitosan-collagen hydrogel, or tricalciumphosphate pretreated with collagen were seeded with
osteoblastlike cells from periost or from bone marrow and were afterwards implanted in 2 ×
2 cm calvarial defects in sheep for 14 weeks. Here, the formation of blood clot containing
different growth factors was discussed as a possible negative factor for the new bone formation
by implanted MSC. McCarty et al. [2010] reported no increase in bone formation from a study
on ovine (5 months old lambs) growth plate injury, where MSC-seeding on collagen-gel foams
hindered the formation of new bone and increased fibrous tissue formation. The authors assumed
that the inflammatory response at the injury side might have overwhelmed the signals imparted
by the scaffold and cells, leading in turn to a tissue regeneration arrest. Furthermore, Lyons et al.
[2010] published a study on rat ciritcal-size calvarial defects, where MSC were seeded on scaffolds
of collagen-glycosaminoglycan and collagen-calcium phosphate. The authors concluded that the
lack of bone formation was again in accordance with the formation of a fibrous capsule, which
might have adversely affected healing by acting as a barrier to macrophage-induced remodelling
when implanted in vivo. In accordance with these findings, in our study there was also a fibrous
capsule around the implants with lymphocytic (silk) or foreign body (PEKK) immune reaction.
Despite the formation of a fibrous capsule, several other factors come into play that might be
responsible for the abscence of an increased bone formation with MSC seeding:
• the cell number; most studies employed cell numbers between 106 and 108 cells per scaffold
[Baba et al., 2010; Kon et al., 2000]. To our knowledge, there is no study which includes
comparison of different cell numbers in an in vivo study. Thus, the ideal cell number is
not known and 106 cells in 3 ml of medium might have been too few to evoke the desired
reaction in vivo.
• the biomaterial; the differential influence of the biomaterial chemistry, topography, stiffness
and architecture on bone tissue engineering has been referenced in literature extensively
and is reviewed in Ciapetti et al. [2012].
• the duration of implantation; PEKK scaffolds already showed a nearly complete filling of
the defect region with bone after 12 weeks. However, for PDLLA a later time point (six
to twelve months) would have been interesting, as degradation of PDLLA in vivo occurs
between six to twelve months after implantation, depending on the scaffold size [Achtnich
et al., 2014; Auras et al., 2010; Hasegawa et al., 2007].
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• the defect size; the defect size was considered undercritical in five out of ten animals. In
critical size defects the results obtained might have been different especially with regard
to the effect of MSC on defect regeneration.
• the animal model; in contrast to other studies, employing sheep for bone tissue-engineering
experiments [Doernberg et al., 2006; Giannoni et al., 2008; Reichert et al., 2010; Xing et al.,
2013], we used much younger animals (1 year old). A potentially faster regeneration in
younger sheep might have lead to closure of half of the defects in contrast to Xing et al.
[2013].
Another important consideration is that craniofacial bones are flat bones and derive from a
different embryonic progeny than long bones. A recently published study emphazised that
calvarial MSC are derived from another precursor cells of the suture niche, and not from the
bone marrow of long bones [Zhao et al., 2015]. Since we seeded the implants with MSC from
pelvic bone marrow, for the sake of easy and painless harvest, differences in the immunological
interplay between the local cells might have occured after implantation.
The clinical application of MSC seeded scaffolds for bone regeneration is still confined to a small
number and there is limited clinical evidence that tissue-engineered grafts can be used safely
[Crowley et al., 2013]. The potency of bone tissue engineering to reconstruct jaw defects in 6
patients was published by Meijer et al. [2008]. After a bone marrow aspirate was taken, stem
cells were cultured, expanded and grown for 7 days on a bone substitute in an osteogenic culture
medium to allow formation of a layer of extracellular bone matrix. This bone substitute was
re-implanted in the patient. Although biopsies showed bone formation in three patients, only in
one patient bone formation was induced by the tissue-engineered construct. In another study
published by Pradel & Lauer [2012], eight children with complete cleft lips and cleft palates
were operated. In four children (group A), the cleft defect was filled with tissue-engineered
bone (autologous osteoblasts cultured on demineralized bone matrix Osteovit R©); as control in
another four children (group B), the alveoloplasty was performed using spongious iliac bone.
Six months post-operatively the mean volume of the cleft was 0.55 ± 0.24 cm3 in group A
and 0.59 ± 0.23 cm3 in group B. However, this difference was not significant. Filho Cerruti
et al. [2007] tested platelet-rich plasma and mono-nuclear cells from bone marrow together with
calcium phosphate scaffolds in 32 patients aged between 45 and 75 years. These scaffolds were
well integrated and had adapted to the cortical bone.
Nevertheless, a direct comparison between cell-free and cell-seeded allograft implantation from
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clinical case reports is difficult as the situation of each patient is complex and individual. How-
ever, none of the above mentioned studies have reported any negative effects of MSC-seeding
for in vivo implantation. Therefore, MSC-seeding of biomaterials for a tissue-engineered bone
graft does not pose an obvious risk.
Bone regeneration continues to be one of the most active areas of tissue engineering research.
Although MSC are thought to influence the cellular cross-talk in the immune response of the
body [Koob et al., 2011],the crucial factors which lead to this goal are not yet understood, given
the general heterogeneous practice for bone tissue engineering. It is of utmost importance to
eventually identify these key factors, so that MSC therapies can help patients with large bone
defects in the clinical setting. This goal can only be reached by systematically intensifying the
basic research on fundamental cell scaffold interactions in vitro and in vivo.
5 Conclusion and Perspective
A tissue engineering approach to defects in cranio-maxillofacial bones would provide several
potential benefits compared to the gold standard of autologous bone grafting, like unlimited
source of bone and elimination of second side operations. The current study was carried out
to investigate the regeneration of sheep critical size calvarial defects after implantation of tissue
engineered constructs made of PDLLA, PEKK, silk and silk + HA.
First, we conclude that materials like silk, which support cell adhesion, proliferation and dif-
ferentiation in vitro, do not necessarily act as a suitable carrier for stem-cell mediated bone
regeneration in vivo. This fact also demonstrates existing differences between the systemic and
isolated investigation of biological questions. The in vivo milieu currently represents a black box
for 3D scaffold implantation, with barely understood framework conditions. Actually, the under-
standing of cell/biomaterial interactions on the in vitro level is only in its infancy. Thus, more
basic research is needed to elucidate these questions. For instance, the stem cell/biomaterial
investigations conducted by Neuss et al. [2008], have shown basic correlations in cell types and
biomaterial compatibility in vitro. Taken one step further, systematic testing of the materials
in a variety of defined 3D structures could be conducted. Other factors like elastic modulus
variation or growth factor modification might be introduced later in this cascade. Finally, a sys-
tematic in vivo comparison of these biomaterials in a defined animal model could be evaluated.
Once enough basic research data is gathered, we might get closer to finding fundamental rela-
tionships and predict in vivo results. Currently, limitations in work power and other resources
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limit such ideal strategies and lead to dispersed knowledge and heterogenous practice.
Secondly, we conclude that MSC application did not lead to an increased bone regeneration
in this particular case, probably due to a fibrous capsule formation around the implants. This
fibrous capsule is thought to prevent the host’s immune response of macrophage (M1 and M2)
invasion for the proper tissue remodelling of forming bone [Lyons et al., 2010]. In this context,
immunohistochemistry for macrophage markers in general (CD68), and specifically M1 and M2
type (CD163 and CCR7), might be beneficial to prove if this hypothesis applies to our case.
To further approximate the factors that influence the role of implanted MSC in vivo, it might be
helpful to combine the experimental settings of two studies, one that reported positive findings
of MSC application in bone tissue engineering, and one that did not. For example, the study
published by Lyons et al. [2010] used rat calvarial defects of 8 mm diameter seeded with MSC
from rat femora and tibiae, which were cultured in DMEM with 10 % FCS. In these critical size
defects, scaffolds of collagen-glycosaminoglycan or collagen-calcium phosphate were implanted
for 4 and 8 weeks. After this period, significantly less bone mass was obtained from the MSC-
treated samples. In comparison, He et al. [2014] used the same animal model and cell source,
as well as similar culture conditions (α-MEM with 10 % FCS) and defect size (7 mm). However,
after implanting a gel of chitosan-alginate-hydroxyapatite for 12 weeks, significantly more bone
mass was obtained form the MSC-treated samples. If these two biomaterials were combined in
one approach, with the time points 4, 8, and 12 weeks the results would add valuable knowledge
to the currently existing questions on what the general conditions are for delivered MSC to act
as bone forming boosters.
In the near future, it is likely that bone tissue engineering in general will be advanced by ex-
panding research of surface modifications and composition of biomaterials, which have already
proven suitable in previous studies, e.g. by their elastic modulus, degradability or biocompatibil-
ity. Furthermore, application of cytokines and growth factors, like bone morphogenic proteins,
are thought to mediate superior bone healing and thus represent another focus of bone tissue
engineering. Recently, the osteogenic induction of embryonic stem cells (ESC) and the creation
of induced pluripotent stem cells (iPSC) have presented new cell sources for bone tissue engi-
neering. However, expansion of ESC and iPSC is challenging, autologous use is not possible in
the case of ESC, and pluripotent stem cells may result in tumour formation after transplantation
[Le Meng Bao et al., 2013]. It is therefore likely, that MSC will keep their prevalent status in
bone tissue engineering in the near future.
Bone tissue engineering will remain a challenging but also highly innovative field in the next
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decades, which will benefit from progress in stem cell research, material sciences and immunology.
Eventually, the knowledge of these disciplines needs to be combined by intense basic research
and standardized in vivo experiments.
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Appendix: Histological Stainings
Table 8: Deaplastization of histological sections prior to staining
Reagent Time
2-Methoxyethyl acetate (2-MEA) 2×30 min
100 % Ethanol 2×2 min
96 % Ethanol 2 min
80 % Ethanol 2 min
70 % Ethanol 2 min
Aqua dest.
Table 9: Hematoxylin & Eosin staining for deplastizised sections
Reagent Time
Mayer’s hematoxylin 10 min
Tap water 5 min
Eosin 1 min
Aqua dest. 1 min
Ethanol 70%, 96%, 100% Each 10 min
Xylene 5 min
Vitro-Clud R© Mounted
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Table 10: Movat’s pentachrome staining for deplastizised sections
Reagent Time
Alcian blue 10 min
Tap water 5 min
Alkaline alcohol 60 min
Running tap water 10 min
Aqua dest. 30 s
Weigert’s ferric hematoxylin 15 min
Aqua dest. 30 s
Running tap water 15 min
Brilliant crocein acidic fuchsin 15 min
(Movat’s staining solution)
0.5 % Acidic acid 30 s
5 % Phosphotungstic acid 30 s
0.5 % Acidic acid 30 s
100 % Ethanol 3×2 min
Saffron du Gatinais 80 min
100 % Ethanol 3×2 min
Xylene
Vitro-Clud R© Mounted
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